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ABSTRACT OF DISSERTATION

THE FUNCTIONAL ROLE OF RNA BINDING PROTEIN RBMS3 AS A TUMOR
PROMOTER IN TRIPLE-NEGATIVE BREAST CANCER CELLS

RBMS3 belongs to the family of c-myc gene single-strand binding proteins (MSSPs)
that play important roles in transcriptional regulation. Here, we show that RBMS3
functions as a tumor promoter in triple-negative breast cancer (TNBC), a highly aggressive
BC subtype. Analysis of RBMS3 expression shows that RBMS3 is upregulated at both
mRNA and protein levels in TNBC cells. Functionally, overexpression of RBMS3
increases cell migration, invasion and cancer stem cell (CSC) behaviors. Moreover,
RBMS3 induces expression of epithelial-mesenchymal transition (EMT) and CSC markers.
Conversely, loss of RBMS3 in TNBC BT549 cells inhibits cell proliferation, migration and
mesenchymal phenotype. Correlation analysis shows RBMS3 is associated with TGF-β
signaling. Mechanistically, RBMS3 interacts with Smad2, Smad3 and Smad4 mRNA and
regulates the stability of these transcripts. Importantly, RBMS3 prevents TGF-β-induced
cytostasis and apoptosis in premalignant cancer cells. Moreover, RBMS3 inversely
correlates with expression of ESRPs, epithelial-specific splicing regulatory proteins that
regulate morphogenesis-associated alternative splicing events. ESRPs suppress EMT
through distinct mechanisms: ESRP1 restricted cell migration, whereas ESRP2 prevented
cell growth. RBMS3 significantly facilitates the EMT process when ESRPs are lost.
Collectively, the studies within this dissertation identify RBMS3 as a positive regulator of
EMT and breast cancer progression by regulating the TGF-β signaling pathway.
KEYWORDS: TNBC, RBMS3, EMT, TGF-β signaling, mRNA stability, and ESRP
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CHAPTER 1. INTRODUCTION
1.1

Mammary Epithelium
About 80% of all breast cancer (BC) are invasive ductal carcinoma. Mammary

epithelial is primarily comprised of two cell types: luminal and basal. The
luminal/epithelial cells constitute the inner layer of the ducts and lobuloalveolar units,
whereas the basal/myoepithelial cells form the outer basal layer. The epithelial duct is
enveloped by a layer of basement membrane (BM), a specialized form of extracellular
matrix rich in collagen IV and laminin. BM contains a repertoire of membrane-tethered
growth factors that can be released by tumor cell-secreted proteases. BM also participate
in signal transduction events via integrin-mediated cell-matrix adhesion, leading to
alterations in cell polarity, invasiveness, proliferation and survival. It is embedded within
a complex stroma, which contains fibroblasts, adipocytes, blood vessels, nerves and
various immune cells [1]. It is well documented that luminal epithelial cells establish
apical-basal polarity during differentiation process. While the apical side is exposed to the
lumen, the lateral surface is intimately associated with adjacent cells and basal cells
through cell-cell contact structures, i.e. tight junctions, adherens junctions and desmosomes
This organization is crucial for the structural integrity of the epithelia [2].

Figure 1.1 Schematic on the main components of mammary duct
Activation of the EMT program in non-metastatic epithelial breast tumors confers
mesenchymal phenotypes and cancer stem cell traits to cancer cells.
1

1.2

Breast Cancer

Statistics
Breast cancer (BC) is the leading cause of cancer-related deaths among women [3].
Approximately 268670 new cases of invasive BC and 41,400 deaths are projected to occur
for the year 2018; this mortality is primarily due to metastasis to other organs,
preferentially the lungs and bones [4, 5]. According to American Cancer Society, there
will be an estimate of 25,990 new cases and 10,590 deaths in Kentucky during the year of
2018 [6]. Although the number of breast cancer cases has increased over time, breast
cancer incidence rates have been fairly stable for the past 10 years. Early diagnosis of the
disease can lead to a good prognosis and a high 5-year survival rate of up to 90% [7].
Risk Factors
Numerous risk factors are associated with breast cancer, including gender, aging,
family history, gene mutations, ethnicity, estrogen receptor (ER) status and unhealthy
lifestyle [7]. Unsurprisingly, breast cancer cases are 100 times more prevalent in women
than in men. While most breast cancers are found in women who are 50 years old or older,
about 11% of all new cases of breast cancer in the United States occur in women younger
than 45 years of age. About 15% of breast cancer patients have family history. The risk of
getting breast cancer nearly doubles if a woman has a first-degree relative (mother, sister
or daughter) who has been diagnosed with breast cancer. 5-10% of breast cancers can be
linked to gene mutations, such as BRCA1 and BRCA2 gene mutations, inherited from one’s
mother or father. For instance, women with a BRCA1 mutation have a 55-65% lifetime
risk of developing breast cancer. About 85% of breast cancer occur in women without
family history, due to genetic mutations that happen as a result of the aging process and
lifestyle in general, rather than inherited mutations. Female breast cancer incidence and
2

mortality rates vary significantly by ethnicity in the United States. Non-Hispanic white
(NHW) and Non-Hispanic black (NHB) women have higher incidence and death rates than
women of other ethnicities [6]. While NHW women develop breast cancer slightly more
than NHB women, however, NHB women tend to die of breast cancer more often, possibly
due to the preference for developing a more aggressive type of tumor. NHW women have
the highest rates of ER+ breast cancer, whereas NHB women have highest rates of ERbreast cancer [8]. According to Johns Hopkins Medicine Health Library, lifestyle-related
risk factors for breast cancer include physical inactivity, poor diet, obesity, frequent
alcohol consumption, breast irradiation, no or late pregnancy (after age 30), early
menstrual periods (before age 12), late menopause (after age 55), recent use of oral
contraceptives, long-term use of combined hormone replacement therapy and exposure to
pesticides or other chemicals.
Molecular Classification
Based on molecular classifications, breast cancer can be divided into at least five
intrinsic subtypes: HER2-enriched, luminal A, luminal B, basal-like and normal breast-like
[9]. HER2-enrich subtype is characterized by overexpression of the HER2 oncogene and
other genes pertaining to the HER2 amplicon. Luminal class comprises the majority of
breast cancer and is further stratified into two subtypes. Luminal A subtype is defined as
ER+, PR ≥20%, HER2-, Ki67 <14%, and, if available, ‘low’ recurrence risk. Luminal B
subtype is ER+, HER2-, and at least one of the following: Ki67 ≥20%, PR- or <20%, and,
if available, ‘high’ recurrence risk [10]. Luminal B tumors are associated with worse
prognosis than that of the luminal A subtype. Generally, the luminal class is characterized
by high proliferation rates, with ER expression, and/or HER expression and low /absent
PR expression. The basal-like subtype is largely defined by lack of expression of ER and
HER2, positive expression of genes characteristic of basal-like cells of the breast and high
3

proliferation index. Normal breast-like subtype displays a triple-negative phenotype (ER-,
HER2- and PR-) and an expression profile similar to those found in normal breast tissue
[11].
1.3

Basal-like Breast Cancer vs. Triple-Negative Breast Cancer
Basal-like breast cancer (BLBC) is a highly malignant subtype of breast cancer. A

large subset of this subtype is characterized by lost expression of ER, HER2 and PR and
high expression of several basal markers, including cytokeratins (5/6, 14 and 17), EGFR,
caveolin 1 and P-cadherin, exhibiting a ‘triple-negative’ phenotype [12]. Triple-negativity
renders this subset of patients less responsive to hormone therapies. Undoubtedly,
tremendous scientific advancements have been made to increase survival rates of BC
patients, however, this is only applicable to BC diagnosed early stages without metastasis.
BLBC accounts for up to 20% of all human breast carcinoma. While approximately
70% of BLBC are TNBC, about 75-80% of TNBC are BLBC. BLBC with ‘triple-negative’
phenotype (TNBC) tend to be aggressive and destructive as it is associated with a high
proliferation index, ensuing brain and lung metastasis, and poor clinical outcome in spite
of treatment [13]. Compared to other molecular subtypes, BLBC still carry the worst
prognosis due to decreased disease-free survival, disease-specific survival and overall
survival. In addition, BLBC patients are at increased risk for early relapse or recurrence
within 3-5 years of diagnosis. Owing to its aggressive phenotype and poor prognosis as
well as limited response to endocrine therapy, effective treatment for BLBC has been an
extremely difficult challenge for breast cancer researchers and clinicians worldwide [14].
1.4

Therapeutics
Traditionally, aggressive breast cancers have been treated with general

chemotherapy drugs anthracycline and paclitaxel. While being more sensitive to this
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regimen in comparison to luminal and normal-like subtypes, over 50% of the BLBC
patients continues to have residual disease and carry a high risk of relapse within 5 years
of diagnosis. Besides, general chemotherapy is limited by nonspecific cytotoxicity, which
poses significant health concerns to patients [14]. Unlike other subtypes, BLBC lacks
expression of molecular targets that responsiveness to effective hormone therapies [15].
Hence, research and clinical trials for targeted therapies are being carried out in the hope
of achieving better therapeutic indices.
DNA repair pathway: BRCA1 mutation has been identified in 15-20% of women
with a family history of breast cancer[16]. BRCA1 deficiency is commonly observed in
BLBC, which provides great opportunity to targeted therapy. BRCA is responsible for
homologous recombination repair of double-strand breaks. Platinum-based chemotherapy
(including cisplatin and carboplatin) induces DNA cross-linking, resulting in double-strand
breaks in cells. Cancer cells with BRCA deficiency become vulnerable to apoptosis upon
treatment of platinum agents. Since poly(ADP-ribose) polymerase (PARP) is involved in
base excision repair for single-strand breaks, PARP inhibitors can be combined with
platinum agents to create more DNA lesions that are less likely to be repaired by the DNA
repair machinery. This cooperative approach utilizes the concept of ‘synthetic lethality’ by
targeting complementary pathways leading to a lethal combination [14]. In 2018, 5 PARP
inhibitors (talazoparib, nirapari, rucaparib, olaparib and veliparib) have finally become
available for patients with BRCA-mutant metastatic breast cancer.
Aberrant activation of the VEGF pathway shown in BLBC has led to therapeutic
strategies to target VEGF and its receptors, including anti-VEGF antibody (Bevacizumab),
VEGFR inhibitor and other receptor tyrosine kinase inhibitors (Sunitinib, etc.).
Although EGFR is upregulated in most BLBCs, the use of a dual inhibitor of EGFR
and HER2/neu (Lapatinib) does not seem to benefit HER2- BLBC patients. Inhibitors of
other downstream kinases, such as MEK and PI3K, are also considered for targeted
therapies[14].
5

Within the past ten years, considerable evidence has highlighted the importance of
immune response in influencing the progression of TNBC. Presence of tumor-infiltrating
lymphocytes (TILs) has been widely recognized as a prognostic factor in early-stage
TNBC. Also, expression of immune evasion molecules in the tumor microenvironment,
such as programmed death-ligand 1 (PD-L1), may influence TNBC prognosis. In TNBC,
PD-L1 expression is about 40-65% in immune cells. Most patients tested as PD-L1+ in
immune cell tumors also had positive PD-L1 expression on tumor cells [17]. Development
of new therapeutic agents against immune checkpoint molecules, such as anti-PD-1 and
anti-PD-L1 monoclonal antibodies has emerged, bringing BC into immunotherapy era
[18].
1.5

Breast Tumor Progression and Metastasis
Like many other tumors, breast tumors progress from an early pre-neoplastic lesion

to the development of clinically detectable distant metastatic foci, which involves a series
of genetic and epigenetic alterations affecting both tumor cells and the surrounding stroma.
Just like other evolutionary processes in nature, the path toward metastatic colonization is
not only extremely complex, but also highly inefficient. Most cells that leave a tumor fail
to seed distant organs and often die on the path [19]. To develop metastasis, epithelial cells
in primary tumor must invade locally and escape from the physical barriers (extracellular
matrix and basement membrane), intravasate into the circulation (lymphatic or vascular
system), extravasate into the parenchyma of distant tissues, survive in the foreign milieu
and re-initiate proliferation programs to form overt metastases [20, 21]. The metastatic
potential of individual cells within the bulk of a tumor is thought to be widely
heterogeneous, which is influenced by various factors, such as tumor size, cell of origin
and type of oncogenic driver mutation [22].

6

1.6

Epithelial -Mesenchymal Transition

Overview
During development and morphogenetic events, epithelial cells undergo a process
called epithelial to mesenchymal transition, or EMT, the concept of which was first
described in the 1980s [23]. During EMT, cells lose epithelial characteristics, such as
intrinsic polarity, cell-cell contact and cell-matrix contact, but gain mesenchymal
properties, including fibroblastoid morphology, increased proliferation and motility,
allowing them to break through the basement membrane and invade surrounding tissues,
even to distant organs [24]. Invasion is a critical step to progression toward a malignant
disease. Morphologically, during the initiation of EMT basal-membrane anchored cells
transform from a cuboidal epithelial-like cell to a spindle-shaped mesenchymal-like cells
[25]. Meanwhile, adherens junction complexes dissemble and the actin cytoskeleton
reorganize from an epithelial cortical alignment into actin stress fibers, which are anchored
to focal adhesion complexes. E-cadherin, a major component of the adherens junctions,
binds tightly to β-catenin with its cytoplasmic domain, which in turn anchors to the actin
cytoskeleton via acting-binding proteins. Loss of E-cadherin epithelial marker from the
basolateral membrane is associated with release of membrane-bound β-catenin to the
cytosol and activation of the canonical Wnt pathway to regulate pluripotency factors
Oct3/4, Sox2 and Nanog, which promotes cell growth, survival and maintenance of
stemness [26]. Loss of E-cadherin, accompanied by induction of mesenchymal markers
(Snail, Slug, Twist1, Zeb1/2, N-cadherin and Vimentin, etc.), represent hallmarks of EMT
and tumor progression. These phenotypic traits appear to be the fundamental molecular
basis for tumor initiation and expansion, metastatic capacity, tumor recurrence and therapy
resistance [27].
The EMT program is activated through contextual signals that cells receive from
their neighbors. In the case of carcinoma, these signals derive primarily from the
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fibroblasts, mesenchymal stem cells and inflammatory cells that are recruited to the stroma
of the tumors and contribute to the formation of a tumor-promoting microenvironment [28].

Figure 1.2 Core signaling pathways that activate EMT
In the context of non-neoplastic cells, several cell-intrinsic signaling pathways (TGF-β,
WNT and NOTCH, etc.) are activated, upon binding of specific ligands, cytokine or growth
factors to their cognate receptors, to induce EMT during embryonic development and
wound healing. Canonical WNT pathway is activated upon binding of WNT ligands to the
Frizzled family of membrane receptors, which leads to the release of β-catenin from the
GSK3β-AXIN-APC complex. β-catenin enters the nucleus and binds to transcription
factors (TF) TCF and LEF to activate genes that drive EMT. The NOTCH pathway is
stimulated upon binding of the Delta-like or Jagged family of ligands to the NOTCH
receptor, which triggers proteolytic cleavage and release of the active, intracellular domain
of the NOTCH receptor (NOTCH-ICD), which translocates into the nucleus to function as
a transcriptional co-activator. TGF-β pathway also crosstalk with PI3K-Akt pathway to
trigger the activation of mTOR complex and NF-κB, p38 MAPK pathway and the RASRAF-MEK-ERK signaling axis. Several cytokines may trigger the phosphorylation,
dimerization and activation of JAK and signal transducer and activator of transcriptional
proteins, which also activate transcription of EMT transcription factors [29]. Details of
TGF-β pathways is discussed below. (Figure cited from Dongre et al.[29])
Classification
EMT is classified into three types based on distinct biological settings under which
they occur, leading to various functional consequences. Type 1 EMT occurs during
implantation, embryo formation and organ development to generate diverse cell types that
share common mesenchymal phenotypes. This class of EMT does not cause fibrosis or
induces an invasive phenotype resulting in systemic spread of the cell through the
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circulation. Type 2 EMT responds to wound healing, tissue regeneration and organ
fibrosis. Following injury and inflammation, this program is activated as a form of repair
event that gives rise to fibroblasts and other related cells in order to reconstruct the tissues
[30]. However, persistent EMT caused by chronic inflammation may ultimately lead to
organ destruction. Type 3 EMT is found in neoplastic epithelial cells at the invasive front
of primary tumors that undergo different extents of phenotypic conversion to invade and
metastasize through the circulation and generate life-threatening metastatic lesions at
distant tissues and organs. While these EMT events are involved in considerably different
biological processes, some genetic elements and regulatory mechanisms may be similar or
well-conserved [24].

Single Cell Migration
Single cells utilize two major modes of migration: amoeboid and mesenchymal.
Amoeboid migration features blebbing, weak adhesions and rapid motility, whereas
mesenchymal migration exhibits extensive stress fibers, polarization and a leader-trailer
edge [31, 32]. Amoeboid migration primarily occurs when cells deform to pass through
pores and fibers in the ECM, whereas mesenchymal migration is accompanied by creation
and expansion of paths as cells degrade and remodel the surrounding matrix [33]. Besides
using matrix metalloproteases (MMPs), cells also rely on Rho kinase, integrin and
actomyosin to enable entry into pores via deformations to the cytoskeleton [34]. The mode
of migration employed by a cell is partially mediated by its adhesivity to the matrix and
the architecture, porosity, composition and mechanical properties of the ECM. For
example, intrinsic activity of actomyosin is the key to transmitting mechanical signals from
the ECM to the cell and generation of contractile force within the cytoskeleton that is
transmitted to adhesion complexes to facilitate movement of cells along the matrix. While
these adhesion complexes are essential for mesenchymal migration, they are less important
for amoeboid migration [31, 35].
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Collective Migration
EMT has traditionally been described as a binary process that involves complete
conversion from epithelial to mesenchymal state. However, recent work points to a greater
flexibility in this transitional process, as increasing evidence reveals that EMT may
subsume a spectrum of intermediate or ‘hybrid’ states, which has been commonly referred
to ‘partial EMT’ [36]. For example, migratory neural crest cells, particularly those arise in
the Xenopus and fish embryos, migrate in a collective manner but have not undergone a
full EMT. These cells gain migratory and invasive properties but have not lost epithelial
properties, as they maintain a significant degree of cell-cell adhesion and cadherin
expression that allow them to migrate together in a coordinated manner using a variety of
modes including sheets, strands, tubes and clusters [32]. Similarly, metastatic carcinoma
cells from spontaneously-arising tumors could have activated EMT program but never
become entirely mesenchymal by completing this process [37].
Overall, two main types of mechanisms exist in cancer cell invasion and
dissemination: the first type may give rise to single cells capable of crossing basement
membrane and invading circulation; the second type where cells migrate in a multi-cellular
cluster by retaining cell-cell contact. While both situations have been observed in mouse
models and clinical specimens, the mechanism underlying these differences in epithelial
plasticity remains elusive. It appears that divergent EMT programs correlate with tumor
subtype in several human breast carcinoma lines. Typically, in the well-differentiated
luminal A, luminal B or normal-like BC cell lines, EMT is associated with persistent
expression of CDH1 mRNA and re-localization of E-cadherin protein, which features a
partial EMT program [36]. Conversely, cell lines harboring a less differentiated basal
signature and loss of CDH1 mRNA and E-cadherin protein features a complete EMT
program (Figure 2). Aiello et al found that partial EMT cell lines are predisposed to form
circulating tumor cell (CTC) clusters more readily than complete EMT cell lines, consistent
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with findings of Giampieri et al., indicating that TGF-β signaling in BC cells prompted a
switch from collective migration to single-cell migration, potentially attributable to
conversion from partial to complete EMT program [38]. CTC clusters showed enhanced
metastatic potential compared to single cells, Aiello et al. speculated that tumors exhibiting
a partial EMT phenotype might exhibit an increased metastatic rate than tumors exhibiting
a complete EMT phenotype[36, 39-41]. Likewise, tumor cells with various degrees of
epithelial-plasticity are prone to metastasize to different sites. Due to complexity and
multimodality in the factors governing metastasis, the relationship between partial EMT
and complete EMT and their respective clinical outcome remain to be defined [42].

Figure 1.3 An epithelial-mesenchymal spectrum exist in breast cancer
Epithelial breast cancer cells that fail to respond to EMT-inducing signals are unable to
undergo EMT, whereas responsive epithelial cancer cells exhibit disrupted autocrine
signaling and transition toward mesenchymal cancer cell state. Once the transition is
complete, these cells may maintain a stable mesenchymal phenotype by autocrine signaling
in the absence of the EMT-inducing signals [43]. The EMT process is thought to be
reversible and is associated with tumor-initiating potential, which peaks at partial-EMT
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phase and diminishes as cells reach a stable mesenchymal state. Listed are some of the
factors that preferentially reside in either cell state [44]. (EMT-TF, EMT-transcription
factors; Figure modified from Chaffer et al. [45])

Figure 1.4 Schematic of differences between partial and complete EMT programs
This figure models two types of tumor cell dissemination. Poorly-differentiated BC cells
are prone to activate a complete EMT program by transcriptional repression of epithelial
genes and activation of mesenchymal genes. Conversely, well-differentiated BC cells, as
observed in most epithelial tumors, modify their epithelial phenotype through an
alternative program involving protein internalization rather than transcription repression,
leading to a ‘partial EMT’ phenotype. As a result, cancer cells utilize this mechanism to
migrate as clusters in the circulation, contrasting with the single-cell migration pattern
defined by traditional concept of ‘EMT’. (Figure modified from Aiello et al. [36])
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Transcriptional Regulation
Most signaling pathways leading to EMT induction converge on the downregulation of E-cadherin, a critical epithelial cell adhesion molecule that serves as the
gatekeeper of EMT [46, 47]. In most cell types, loss of functional E-cadherin results in
decreased cell adhesion, leading to uncontrolled cell growth and metastasis.
Molecular events of EMT are transcriptionally controlled by master regulators such
as transcription factors Snail, Slug, ZEB1/2 and Twist1/2. In most physiological EMT
conditions, overexpression of Snail, Slug, ZEB1/2, or Twist1/2 in epithelial cell lines
typically induces EMT [25]. Snail and Slug initiate EMT by repressing epithelial genes
like E-cadherin through binding to E-box DNA sequences of their carboxy-terminal zincfinger domain, while ZEB1/2-mediated transcriptional repression often requires additional
recruitment of a C-terminal-binding protein (CTBP) co-repressor [48]. Twist1/2 belongs
to the basic-helix-loop-helix (bHLH) family of transcription factors and interact with E
boxes by its bHLH domain and repress transcription of E-cadherin in a way similar to that
of Snail. Twist, Snail and Slug work synergistically, controlling an overlapping and distinct
sets of genes, during tumor progression. Apart from its role as a transcriptional repressor,
Twist also serves as a transcriptional activator by recruiting BRD4 to coordinate EMT
induction [9]. These transcription factors also regulate genes extensively involved in
motility, proliferation, differentiation and survival [25, 49, 50].

Post-transcriptional Regulation
Since the discovery of ribonucleoproteins (RNP), interest in RNA biology has
escalated rapidly. Given the intimate connection from transcription to translation in
eukaryotic gene regulation, many studies have suggested that post-transcriptional events
involving collections of mRNAs are tightly coordinated [51]. Post-transcriptional
regulation of gene expression is emerging as a critical factor for many cellular and
developmental processes. In many cases, RNA-binding proteins (RBPs) are the major
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players by interacting with either coding or untranslated regions of mRNA [52]. RBPs are
involved in every step of RNA metabolism in terms of post-transcriptional regulatory
processes. The subcellular localization and level at which an (RBP) is expressed is crucial
in determining its function. Nuclear RBPs primarily regulate nascent mRNA (pre-mRNA)
processing events, including capping, splicing, 3’-end cleavage, polyadenylation and
nuclear export. Cytoplasmic RBPs coordinate translation-associated events, such as
mRNA transport, competitive or co-operative control of the translation machinery and
regulation of mRNA stability [53].
1.7

Signaling Pathways that activates EMT
TGF-β Signaling
Transforming growth factor-β (TGF-β) is a prototypic member of a large family of

evolutionarily-conserved cytokines that includes bone morphogenetic proteins, activins,
growth differentiation factors, Nodal and inhibins. Virtually all human cell types are
responsive to TGF-β, as it was evolved to regulate the expanding systems of epithelial and
neural tissues, immune system and wound repair [54]. TGF-β play critical roles in
embryonic

development,

cell

differentiation,

cellular

homeostasis

and

tissue

morphogenesis [54]. Mammals express three distinct TGF-β ligands (TGF-β 1-3) and three
high-affinity receptors (TβR I-III). TβR-I and TβR-II both harbor Ser-Thr protein kinases
in their cytoplasmic domains that are essential for intracellular signaling. TβR-III, the most
abundant TGF-β receptor, lacks intrinsic enzymatic activity and modulates cellular
responses to TGF-β by forming various TβR combination. In canonical TGF-β signaling,
ligand binding of TGF-β to TβR-II stimulates recruitment, transphosphorylation and
activation of TβR-I by TβR-II. Activated TβR-I binds and phosphorylates transcription
factors Smad2/3, which forms complex with common transducer Smad4. The heteromeric
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Smad2/3/4 complex accumulates in the nucleus, interact with other transcription factors
and regulate gene expression in a cell- and context-specific manner [24, 55].
TGF-β also signals through several non-Smad pathways, including p38 MAPK,
JNK MAPK, mTOR, RhoA, Ras, PI3K/Akt, PP2A/p70S6K, c-Src, 4E-BP1 and eEF1A1
[56]. Smad4 is essential for most but not all TGF-β-regulated transcriptional responses.
TIF1γ (transcription intermediate factor 1γ, or TRIM33) is another TGF-β signal mediator
that interacts with receptor-activated Smad2/3 in competition with Smad4 and engages in
TGF- β-induced erythroid differentiation [57]. Most of these noncanonical TGF-β
signaling pathways have been established in cell culture conditions, but their relevance to
human cancer remains to be investigated.

Figure 1.5 Schematic of TGF-β/SMAD-induced transcriptional responses
Activation of the pathway is initiated by binding of extracellular TGF-β ligands to the
transmembrane TβR2 (TGF-β receptor 2), leading to recruitment and oligomerization of
TβR1. Activated TβR1 phosphorylates intracellular mediator Smad2 or Smad3, termed
regulatory-SMADs (R-Smads). R-Smads relay the signal to the cytoplasmic effector CoSmad (Smad4, etc.), which enables translocation of the R-Smad-co-Smad complex into the
nucleus and recruitment of additional co-transcriptional activators, repressors and/or cofactors to regulate expression of target genes. (TFs indicate Transcription Factors; ‘P’
indicates phosphorylation; Double wavy lines indicate DNA)
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Figure 1.6 Overview of Smad and non-Smad arms of TGF-β signaling
TGF-β signals through specific TGF-β Ser/Thr kinase receptors (TβR1 or TβR2).
Activated TβR1 induces Smad2/3 phosphorylation, leading to hetero-oligomerization of pSmad2/3-Smad4 and translocation of the complex to the nucleus to regulate target gene
expression. Smad7 is one of the TGF-β target genes that functions as an inhibitory Smad
by recruiting E3 ligase SMURF1/2 to TβR1. ARKADIA-RNF12-AXIN2 enhances TGFβ signaling by targeting Smad7 for polyubiquitination and degradation [58, 59]. In addition,
USP4/15 deubiquitinases can remove ubiquitin chains from TβR1 to stabilize the TβR1
receptor. FAF1 targets TβR2 for degradation by recruiting the VCP/E3 ligase complex,
thereby limiting excessive TGF-β response. Non-Smad signaling include several branchs:
PI3K-Akt-mTOR pathway, ERK, p38 and JNK MAPK cascade, and pathways downstream
of Rho-like GTPase signaling intermediates [60, 61]. Both TβR1 and TβR2 are directly
involved inthe activation of PI3K-Akt pathway by interacting with p85 sub-unit of PI3K
[62]. Activation of Akt by PI3K induces mTOR, which controls translational responses.
TGF-β-mediated activation of JNK and p38 MAPK pathway is partly mediated through
ubiquitin ligase tumor necrosis factor receptor-associated factors 4 and 6 (TRAF4/6). TGFβ-stimulated interaction of TRAF4 with TβR1 induces K63-polyubiquitination of TRAF4
and, as a consequence, activation of TAK1, a MAPKKK family member. Additionally,
TRAF6-TβR1 interaction induces auto-ubiquitination of TRAF6 and Lys63-linked
polyubiquitination of TAK1 [63]. Concomitant activation of TAK1 results in activation of
its downstream target mitogen-activated protein kinase 3,4 and 6 (MKK3/4/6), leading to
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subsequent activation of p38 MAPK and JNK. In response to TGF-β, autophosphorylation
of TβR1 and TβR2 triggers the recruitment of Grb2 and SOS, which activates Ras and RafMEK-Erk MAPK cascade. GTPase RhoA and its target ROCK are also induced to promote
actin stress fiber formation and mesenchymal characteristics [64-66]. (Figure adapted from
Feng Xie, et al. [66])
Under physiological settings, the anti-proliferative actions of TGF-β counteract the
effects posed by local mitogenic stimulation. Under intense mitogenic stimulation,
however, the TGF-β pathway triggers cytostasis or apoptosis, denpending on the intensity
of the proliferatife signals, to offset increased cell proliferation. TGF-β prevents cell cycle
entry into S-phase by upregulation of cyclin-dependent kinase inhibitors (such as p15 and
p21) and suppresion of c-Myc [67]. Conversely, TGF-β-induced apoptosis include several
Smad-dependent and –independent mechanisms depending on the cellular context. TGF-β
preferentially drives differentiation of mesenchymal precursors towards fibroblasts [68].
In addition, TGF-β also suppresses cell proliferation and tumor formation by blocking the
production of paracrine factors in stromal fibroblasts and inflammatory cells [54].
Collectively, TGF-β prevents tumor progression by regulating not only cell proliferation,
differentiaion and survival, but also the cellular microenvironment .
TGF-β signaling is implicated as the primary inducer of EMT. In normal epithelial
cells and early tumorigenic cells, TGF-β signaling inhibits uncontrolled growth by
inducing cell cycle arrest and apoptosis. However, during advance stage of tumorigenesis,
TGF-β ligands are frequently augmented, which may be formed by tumor cells or tumorassociated immune and stromal cells in the microenvironment of basal-like breast tumors
[13, 69]. Malignant cells evade TGF-β suppressive effects either through mutational
inactivation of core compoenents of the TGF-β pathway or just by disabling the tumor
suppresive arm of the pathway, allowing cancer cells to freely usurp the remaining TGF-β
circuit to their advantage. Particularly, breast cancer seem to preferentially disable the
tumor-suppressive arm of TGF-β to benefit from tumor-derived TGF-β by using its as a
shield against antitumor immunity. Collectively, TGF-β pathway facilitates cancer
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progression and metastasis by inducing EMT, inhibiting immunosurveillance, activating
fibroblasts and neoangiogenesis. This dramatic conversion in TGF-β function is recognized
as the ‘TGF-β paradox’ and its detailed molecular mechanisms have not been elucidated
entirely.
At the transcriptional level, TGF-β directly or indirectly activates EMT by
upregulation of transcription factors, including Snail and EF1, leading to repression of
epithelial marker genes (e.g. Occludins, Claudin and E-cadherin)

and concomitant

induction of mesenchymal markers (e.g. Vimentin, Smooth Muscle Actin and N-cadherin)
[70]. TGF-β also promotes EMT by a variety of Smad-dependent and –independent effects
on junction complexes Smad-induced expression of HMGA2 increases expression of Snail,
Slug and Twist. TGF-β also collaborates with other signaling pathways to activate EMT
and maintain the mesenchymal phenotype of metastatic tumor cells [71].
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Figure 1.7 Roles of TGF-β in cancer progression
In normal epithelium and pre-malignant cells, TGF-β enforces cellular homeostasis and
suppresses tumor progression directly through cell-autonomous tumor sppressive effects
or indirectly through effects on the stroma. Malignant cells circumvent TGF-β suppressive
effects either through mutational inactivation of core compoenents of the TGF-β pathway
or by disabling the tumor suppresive arm of the pathway, allowing cancer cells to freely
usurp the remaining TGF-β circuit to their advantage. Therefore, cancer cells that lose
TGF-β tumor-suppressive resoponses utilize this machinery to initiate metastatic
dissemination, growth factor production and immune invasion [54]. (Figure adapted from
Joan M [54].)
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Wnt Signaling
Three Wnt signaling pathways (canonical pathway, Wnt-calcium pathway and
planar cell polarity pathway) operate in response to the binding of 19 distinct Wnt ligands
to the Frizzled family of cell surface receptors [72]. Canonical Wnt pathway triggers a
series of signaling events that culminate in the nuclear translocation of β-catenin, acting as
a transcription co-factor, to induce the expression of a broad range of target genes involved
in cell proliferation, differentiation, cell fate specification and tumorigenesis [73]. Wntmediated activation of the EMT program involve direct transcriptional activation of various
EMT-TFs, including TWIST, SNAI1, SNAI2, ZEB1, CDH2 and repression of CDH1. Ecadherin, a part of the adherens junctions complex that forms lateral connections between
adjacent epithelial cells, is a negative regulator of the canonical Wnt pathway by
sequestering the entire β-catenin pool at the cell membrane. In particular, inhibition of
SFRP1, a Wnt antagonist, induces EMT-like changes in immortalized mammary epithelial
cells TERT-HMLE and sensitizes them to TGF-β-induced EMT [74]. Additionally, TGFβ downstream target Smad7 cooperate with β-catenin to control the expression of several
genes associated with cell adhesion and metastasis [75, 76].
Non-canonical Wnt signaling cascade induces EMT in a β-catenin-independent but
PKC-dependent manner. Noncanonical ligands has been found to be upregulated in human
epithelial cells that have completely turned into a highly mesenchymal state, compared to
those that reside in an intermediate state [77].
Notch Signaling
This pathway is primarily implicated in regulating cell fate decisions,
differentiation and proliferation. Four isoforms of single-pass transmembrane Notch
receptors (Notch -4) are known to bind the Delta-like or Jagged family of transmembrane
ligands, which triggers a series of proteolytic cleavage events that lead to production of the
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active, intracellular fragment termed NICD [78, 79]. NICD translocates to the nucleus and
associate with binding partners and factors, leading to expression of a cohort of target
genes. NICD contains multiple domains, the RBPJ-κ association module (RAM), Ankyrin
repeats (ANK domain) and transcriptional activation domain (TAD). TAD domain consists
of nuclear localization sequence (NLS) and PEST domain that regulates receptor
degradation [80]. PEST domain is likely to play a role in E3 ubiquitin-mediated turnover
of NICD through ubiquitin-proteasome and lysosomal pathways. Mutations in the PEST
domain have been demonstrated to increase the half-life of Notch 1-3 and upregulation of
Notch downstream targets in TNBC [81]. During mammary gland development, Notch
seems to be differentially expressed between cell subtypes. While Notch1 is higher in the
luminal cells, Notch1/3 appear to mark the luminal progenitor cells. Overexpression of
Numb, a negative regulator of Notch signaling by ubiquitylation and degradation of NICD,
or downregulation of Cbf-1/RBPJ- κ, increases mammary stem cell (MaSC) proliferation
and expands the pool of basal cells. Moreover, Notch4 is involved in promoting stem cell
renewal of mammospheres [82]. Therefore, reduced Notch signaling is crucial to propagate
the basal cell and MaSC population [83]. Notch pathway has also been implicated in
regulating EMT in several different types of cancer [84-91]. Embryos lacking Notch1 or
its partner RBPJ, fail to express Snail and thereby cannot undergo endocardial EMT [88].
Notch activates EMT by transcriptional regulation of several EMT-TFs such as SNAI1 and
SNAI2 [92]. Numb has been shown to abrogate Notch1-mediated EMT in TNBC [93],
whereas the E3 ligase MDM2 contributes to Numb degradation, leading to activation of
Notch in BC. Targeting MDM2 led to a reduction in Notch signaling in MCF7 cells [94].
Notch also crosstalk with TGF-β pathway to induce EMT, via interaction of Smads with
NICD and other TFs to regulate mesenchymal fate-related genes. TGF-β also can induce
expression of Notch ligands such as Jagged 1, which act in an autocrine fashion [88].
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Growth Factor Signaling
Binding of growth factor receptors by their cognate ligands stimulates receptor
dimerization

and

activation

of

receptor-associated

tyrosine

kinases

(RTKs).

Phosphorylation of these receptors enables activation of the PI3K-Akt, ERK-MAPK, p38
MAPK and JNK pathways, promoting cell proliferation, migration and motility via
induction of EMT [95]. Upon EGF stimulation, Stat3 binds to the promoter of TWIST in
MCF7 cells. EGF was also shown to induce nuclear co-localization of Snail and phosphoSmad2/3 in MDA-MB-231 cells [96, 97]. Fibroblast growth factor (FGF) has been
implicated with the induction of EMT via MAPK and MEK-ERK pathway [98, 99].
Hepatocyte growth factor (HGF), the ligand of MET tyrosine kinase receptor, is a potent
activator of EMT by upregulating Sail1 [100]. Platelet-derived growth factor (PDGF) is
found to provide an autocrine feedback loop to maintain the neoplastic human mammary
epithelial cells in a more mesenchymal phenotype [101].
1.8

RNA Binding Protein
As soon as a gene is transcribed, many post-transcriptional events are expected to

occur before the protein product is synthesized, such as mRNA processing,
nucleocytoplasmic export, mRNA localization, mRNA stabilization and translational
regulation. A majority of these events are controlled through a complex network of
RNA/protein interactions involving recognition of specific target mRNAs by RNA binding
proteins (RBPs) [102]. Post-transcriptional regulation of gene expression results from
spatiotemporal equilibrium and dynamics between the regulatory sequences found on the
mRNA, RBPs as well as the signaling pathways that modify them under a particular
cellular context. Alteration of any of these determinants may disturb the equilibrium and
thus the expression level of a given protein, causing a broader effect to cell homeostasis.
Deregulation of gene expression may enable the cell to re-enter cell cycle, conferring them
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growth or motility advantage over normal cells [102]. Currently, approximately 500 RNA
binding domains (RBDs) have been characterized in the human genome.
While a growing body of reports published on the association of specific factors
with a given RNA, these studies merely unveiled isolated pieces of jigsaw puzzle out of
the entire landscape of post-transcriptional regulation. The dynamics and kinetics of the
pivotal RBPs and their targets must be fully addressed in order to comprehend how to
achieve a certain expression level of a given gene and how it affects oncogenesis.
1.9

Alternative Splicing
Overview
Splicing is largely carried out by the main spliceosome, a complex machinery

composed of five small nuclear ribonucleoprotein particles (U1, U2, U4, U5 and U6
snRNP) and a large variety of auxiliary proteins [103]. Alternatively, a small number of
introns are processed by the minor spliceosome comprised of U11, U12, U4atac/U6atac
and U5RNPs [104]. The main spliceosome machinery recognizes short consensus
sequences at the exon-intron junctions and catalyzes two transesterification reactions
necessary for the inclusion of exons and removal of introns. Due to the short and degenerate
nature of the splice sites, additional factors are often required to assist the spliceosome
function. The activity of the spliceosome is strictly regulated by both cis-acting sequences
on the pre-mRNA and transacting factors, which may either enhance or inhibit recognition
of splice site and splicing reaction [105]. Two main classes of RBPs that regulate splicing
by binding to the cis-acting elements are Ser/Arg rich (SR) proteins and the heterogeneous
nuclear ribonucleopreoteins (hnRNPs), one exert positive regulation and another function
as antagonistic inhibitor of splicing [106].
Alternative splicing adds an additional layer of complexity to the splicing process
by the presence of exons characterized by weak element defining exon-intron boundaries.
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Differential assortment of weak or variable exons allows a gene to produce multiple splice
variants, encoding protein isoforms with different or even opposite function of distinct
patterns of spatiotemporal expression [107]. The advent of high-throughput sequencing
technologies has revealed that over 95% of human genes are estimated to undergo
alternative splicing to expand proteome diversity by producing multiple mRNA and protein
isoforms per gene [108]. This RNA processing event is mediated by the intricate interplay
between splicing factors and defined RNA sequences/splice sites within the pre-mRNA.
Pre-mRNA splicing occurs in multivariate modes, the most common of which is alternative
inclusion of cassette exons. Other common modes include alternative 5’ or 3’ splice sites,
intron retention, mutual exclusion of cassette exons, exon scrambling and trans-splicing.
While tissue specificity for the dominant isoform per gene is found in more than half of all
genes, switch-like events occur in about 35% of genes between any two tissue types [109].
Alternative splicing plays a pivotal role in controlling core cellular processes, such
as

proliferation, metabolism,

apoptosis,

physiological

decisions,

induction

of

differentiation and maintenance of pluripotency. Aberrant regulation of alternative splicing
contributes to the onset or progression of several human diseases, including cancer [107].
As documented by numerous studies, specific splice variant signatures are strongly
associated with particular types of cancer, thus representing suitable targets for the
development of valuable antitumor therapies. In light of this, great interest has arisen for
the investigation of the tumorigenic vs. normal splicing patterns and the search of
approaches to switch splicing patterns from tumoral variant toward non-tumoral isoform.
Specifically, two possibilities have been proposed: one is to target the specific activity of
the oncogenic splice variant, another is to target the mechanism driving the aberrant
splicing event [107].
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Epithelial Splicing Regulatory Proteins and EMT
Alternative splicing must be tightly-regulated, in a spatiotemporal manner, to
ensure the expression of functionally different splice isoforms. Changes in cellular
phenotype, such as EMT, is modulated at the level of alternative splicing by a number of
splicing factors. Alternative splicing was the first post-transcriptional mechanism linked to
EMT [110]. Epithelial splicing regulatory protein (ESRP) 1 and 2 were first identified as
specific regulators of fibroblast growth factor receptor-2 (FGFR2) splicing as well as other
epithelial-specific variants. Cell type-specific expression of epithelial and mesenchymal
isoforms of FGFR2 splicing occurs by inducing the switch of mutually exclusive exons
IIIb and IIIc, respectively. Microarray analysis of PNT2 epithelial cells after ESRPs
knockdown showed that loss of splicing program alone can induce some of the phenotypic
changes that occur during EMT, suggesting that the ESRP-regulated splicing program is
an essential aspect of the epithelial phenotype and many EMT-associated cellular changes
are due to functional alterations of proteins that undergo isoform switch during this process.
Role of Alternative Splicing in Breast Cancer
Aberrant alternative splicing (AS) events are linked to BC onset and progression.
Carriers of BRCA1 mutations are predisposed to breast cancer with lifetime risk of up to
80% than non-carriers [111]. Mutation of the BRCA1 gene within specific sequences
affects the binding of splicing factors, leading to AS events of BRCA1 and production of
variants that lack functional domains of the protein, thus compromising its tumor
suppressor activity [112, 113]. Similarly, point mutations may also occur in splicing
factors, resulting in inaccurate AS of cancer-related genes, such as favoring protooncogene splice variants over tumor suppressor splice variants [114]. Deregulation of
splicing factors, and also other RBPs, can also cause repercussions on splice site selection,
and thereby are associated with development and progression of BC (Figure ) [112].
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1.10 mRNA Stability and Translation
The majority of mRNA regulatory elements involved in modulation of posttranscriptional events are situated within the 5’ and 3’-UTR, where they act as platforms
for the assembly of regulatory factors. While the 5’-UTR is primarily engaged in
controlling mRNA translation, the 3’-UTR regulate multiple aspects of the mRNA
metabolism, such as nuclear export, cytoplasmic localization, mRNA stability and
translational efficiency [115-117].
Tight regulation of mRNA half-life plays a pivotal role in normal cell functions.
Substantial stability renders a mRNA available for translation for a longer time, yielding
high levels of protein products. Differences in the length and structure of the 3’-UTR
expands the mammalian gene products generated by AS and alternative polyadenylation
[118, 119].
The structure of an mRNA- 5’ untranslated region (5’-UTR), 5’ cap structure, open
reading frame (ORF), 3’ untranslated region (3’-UTR) and 3’ terminal poly (A) tailgoverns mRNA stability and translational efficiency. RNA sequence elements like 5’ cap
and 3’ poly(A) tail are universally present in all mRNAs and convey constitutive processes
without apparent selectivity of one mRNA relative to another [109]. However, numerous
cis elements have been described which pose effects on stability and/translation of given
subsets of mRNAs. In the 5’-UTR, the iron-response elements, JNK-response elements
and turnover determinants are present in the chemokine ligand 1 (KC) mRNA. These
elements dictate the activities of trans factors which elicit responses on several processes
such as translation, turnover, storage and transport. mRNA decay elements such as CRD1 have been observed in the ORF of mRNAs such as c-fos, c-myc and β-tubulin. 3’-UTRs
are well recognized to contain turnover and translation determinants that bind RBPs to
target

specific

mRNA

for

stabilization/destabilization

or

translational

activation/repression. To-date the most commonly found 3’-UTR cis element are the AU-
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rich elements (AREs), which often contain a variable number of AUUA pentamers,
sometimes harbored within a U-rich region. AREs are found on numerous mRNAs
encoding oncogenes, cytokines, interleukins, TNF-α and cell-cycle regulators such as cfos, c-myc and cyclins A, B1 and D1. Many of them are overexpressed during cellular
transformation due to mRNA stabilization or enhance translation [102, 109]. Other specific
secondary structures such as stem-loop motifs are found on 3’-UTR of cell cycle-regulated
histone mRNAs [109]. Together, these regulatory elements serve as binding sites for a
variety of RBPs that modulate mRNA stability and translation efficiency. Given the
abovementioned involvement of these regulatory elements and trans-acting factors (e.g.
RBPs), alterations in any of these components can cause major impact on mRNA half-life
and/or translation, resulting in aberrant levels of expressed protein and hence metabolic
changes leading to disease.
Regulation of mRNA stability and translation occurs via interaction of cis elements
with trans-acting factors, which in turn target the mRNA for rapid degradation or protect
it from nuclease access and/or regulate translational efficiency.
Several trans-acting factors are emerging as core regulators of expression of
cancer-related genes. In general, the levels of RBPs are frequently elevated in cancer. Each
RBP is likely to regulate a discrete but broad subset of target transcripts simultaneously,
thus leading to an expanding functional network of changes which pose significant
consequences for cancer cell biology [120]. Some of the changes occur at the level of AS,
generating variants that promote multiple aspects of tumorigenesis, which enables cancer
cells to rapidly adapt to adverse conditions encountered during transformation, leading to
chemoresistance.
Cancer genes are characterized by their altered gene expression and/or activity
leading to abnormal phenotype. Such changes confer the cell with competitive growth
advantages: enhanced cell division, resistance to cell death, increased angiogenesis,
invasion and metastasis, and evasion of immunosurveillance. Apart from gene mutation,
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additional mechanisms also contribute to abnormal level of gene products in cancers, such
as gene dosage, gene transcription, post-transcriptional control of the mRNA and regulated
proteolysis [109].
RBPs that Regulate mRNA Stability and/or Translation
RBPs influence translational efficiency primarily through three modes of action:
direct interaction with mRNA, bridging other RBP from its target mRNA, and tag a mRNA
for rapid deadenylation/degradation or to protect it from nucleases [121].
One of the best studied mRNA stabilizing protein is HuR, a ubiquitously expressed
member of the embryonic lethal abnormal vision (ELAV) family of ribonucleoproteins.
HuR regulates cyclin A and B1 mRNA stability in a cell cycle-dependent fashion by
nuclear-cytoplasmic shuttling of HuR. Other members of this family, such as neuronal
specific HuB, HuC and HuD, also participate in mRNA stabilization. HuR is well known
of its ability to recognize AU-rich elements (AREs) found on 3’-UTR of specific mRNAs,
which influences different cellular processes such as proliferation, differentiation,
apoptosis, inflammation, stress response and cancer [51, 122]. Snail mRNA is one of the
HuR targets. The binding of HuR to Snail 3’-UTR is significantly increased following
exposure to H2O2, which triggers EMT in several cell types [123]. HuR has been reported
to bind to p53 3’-UTR to enhance its translation [124].
CUG triplet repeat RNA binding protein 1 (CUGBP1), or ELAV-like family
member 1, is another example of mRNA stabilizing protein. CUGBP1 and CUGBP2 are
members of the CELF (CUGBP and ETR3-like factors) family of RNA binding proteins.
Upon binding to the ARE in the cyclooxygenase-II (COX-2) mRNA, CUGBP stabilizes
COX-2 mRNA to repress its translation [102].
Several RBPs have opposite effects on mRNA stability. AU-rich element RNA
binding protein 1 (AUF1), or hnRNP D, consists of four isoforms of 37, 40, 42 and 45 kDa.
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AUF1 is correlated with rapid degradation of ARE-containing mRNAs [125].
Tristetraprolin (TTP or ZFP36), characterized by two tandem repeat zinc finger motifs,
binds to AREs and mediate mRNA decay [126]. Several other targets of TTP include TNFα, VEGF, IL-1, IL-8, GM-CSF and HIF-1 [127]. KH-type splicing regulatory protein
(KSRP) is another example of mRNA decay protein by binding to AREs [128].
1.11 Introduction to RBMS3
RNA binding motif, single-stranded interacting protein 3 (RBMS3) belongs to the
small family of c-myc single stranded binding proteins, which contains two
ribonucleoprotein domains (RRM).RBMS3 was initially identified as binding to an
upstream element of the mouse collagen α2 gene promoter [129]. RBMS3 was later shown
as a tumor suppressor by regulating G1/S progression, cell proliferation and inhibit
angiogenesis in gastric cancer and nasopharyngeal carcinoma [130-132]. Downregulation
of RBMS3 was also found to facilitate development and progression of lung squamous cell
carcinoma. RBMS3 was to be expressed in activated hepatic stellate cells, a type of
mesenchymal cells of the liver, and liver fibrosis [133]. Despite this, the effect of RBMS3
appears to be controversial. Recent literature suggested that loss of RBMS3 confers
chemoresistance to epithelial ovarian cancer via activation of miR-126/β-catenin/CBP
signaling [134]. RBMS3 has been reported to function by binding to the 3’-UTR of its
targets to increase mRNA stability and half-lives in gastric cells, activated hepatic stellate
cells and zebrafish embryo [133, 135, 136].
One of the best developmental function of RBMS3 is studied in zebrafish. Zebrafish
RBMS3 was transiently expressed in the cytoplasm of condensing neural crest cells within
the pharyngeal arches. Morphants for RBMS3 demonstrated severe craniofacial defect
phenotype resembling cartilage/crest defects observed in Tgf- βr2:Wnt1-Cre mutants, with
reduced proliferation of prechondrogenic crest and significantly altered expresison for
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chondrogenic/osteogenic lineage markers. Zebrafish RBMS3 posttranscriptionally
regulate one of the major cartilage differentiation effectors, the TGF-βr pathway, to driving
central neural cells down to a chondrogenic lineage [136].
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CHAPTER 2. RATIONALE, SPECIFIC AIMS AND INNOVATION

Rationale and Specific Aims
Triple-negative breast cancer (TNCB) represents up to 15-20% of all breast
cancers and show enhanced invasiveness, metastatic potential and worse prognosis.
Metastasis, the cause of 95% of cancer-related deaths, represents the biggest clinical
challenge accounting for the vast majority of cancer-related deaths. However, effective
therapeutic strategies targeting breast cancer metastasis are still scarce due to
spatiotemporal intra-tumor cellular heterogeneity. Improved approaches to identify TNBC
in the clinic and better understanding of the molecular programs that defines the metastatic
potential of TNBC are urgent.
Cancer metastasis is mediated by cellular interactions in response to signals from
the tumor microenvironment affecting dynamic remodeling of the actin cytoskeleton
contributing to the modulation of cell adhesion, migration and invasion. TGF-β is known
to be highly expressed in the breast tumor microenvironment. TGF-β acts as a negative
growth factor via growth inhibition and apoptotic induction in healthy cells and early
tumor cells, however, it switches to promoting cell invasion, angiogenesis and cell
adhesion and migration at later stages of tumorigenesis [137]. While the mechanism
underlying the switch from a growth suppressor to a metastasis promoter is largely
unknown, understanding how cancer cells interpret TGF-β signals from the
microenvironment is necessary for elucidating the process. Previous evidence from
zebrafish demonstrated the physical interaction between RBMS3 and Smad2/3
transcripts, establishing the role of RBMS3 in regulating chondrogenesis by stabilizing
the pool of Smad2/3 transcripts in order to maintain a high level of TGF-β signaling and
thus cells remain at the mesenchymal state. Since RBMS3 is highly expressed in BLBC
cells and its function in BC is unknown, here we propose BLBC cells exploit the same
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mechanism to fuel the TGF-β pathway. Hence, the specific aims of the first part of my
work are: 1) to study the function of RBMS3 in BC cell migration and invasion; 2) to
investigate the role of RBMS3 in TGF-β signaling.
90% of BC metastasis occurs in the mammary duct. Although metastatic BC cells
often express basal markers, the basal/myoepithelial layer is not thought to be the source
of metastasis, but rather a barrier for metastasis. Therefore, it becomes an enigma how the
organized luminal cells break this entity and spread to other organs. At the
posttranscriptional level, the identity of luminal cells is strictly governed by lineage
determinants like the master regulator ESRP1/2 proteins. ESRPs not only organize cell
polarity, cell migration and proliferation, but are also known to suppress the expression of
EMT genes. Unlike the less metastatic luminal BC cells that overexpress ESRPs, metastatic
TNBC cells express little to no ESRPs. Conversely, in our preliminary work, we found that
TNBC cells preferentially express an RBP, RBMS3, which is absent in luminal BC cells.
The mutually exclusive pattern of ESRPs and RBMS3 led us to speculate that RBMS3 is
a mesenchymal lineage determinant that may be required for enhancing or maintaining
mesenchymal phenotypes. Therefore, we hypothesize that RBMS3 is a tumor promoter in
the TNBC cells. We also speculate that if we swap the ESRPs with RBMS3, luminal BC
cells may lose their epithelial identity and adopt mesenchymal features. Therefore, the
specific aims of the second part of my work are: 1) to understand the functional similarities
and differences of ESRP1, ESRP2 and RBMS3; 2) to perform RNA-seq analysis on the
established cells and study the posttranscriptional profiles to understand the networks
controlled by these RBPs; and 3) to identify common targets that may be critical for BC
cell migration, adhesion and invasion.
Overall, my hypothesis is that RBMS3 is a tumor promoter involved in regulating
RNA metabolism and splicing in TNBC.
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Innovation
The study is based on the hypothesis that RBMS3 plays tumor-promoting roles through its
abilities to regulate RNA metabolism or splicing. The overall innovations are: 1) This is
the first study to demonstrate the oncogenic function of RBMS3, which will provide a
better understanding to the impact of RBMS3 on BLBCs. 2) This is also the first to
delineate RBMS3-mediated regulation of RNA metabolism and splicing in BC. 3) This
study proposes a novel strategy to study three RBPs by swapping ESRPs with RBMS3 in
luminal BC cells.
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CHAPTER 3. MATERIALS AND METHODS
3.1

Cell Lines and Cell Culture
The MCF7, MDA-MB-231, MDA-MB-157 and Hs578T breast cancer cell lines

were grown in Dulbecco’s modified Eagle’s medium (DMEM)/F12 supplemental with 10%
fetal bovine serum (FBS), 100μg/mL streptomycin and 100 unit/mL penicillin. T47D and
BT-549 breast cancer cell lines were grown in RPMI1640 plus 10% FBS. All cells were
cultured at 37°C in humidified air containing 5% CO2. For establishing stable clones of
RBMS3 knockout or overexpression, transfected cell lines were selected with puromycin
(1 μg/mL) for 4 weeks followed by selection of single clones.

3.2

Plasmids, Drugs, Antibodies and Primers
Stable RBMS3 knockout cells were generated by lentiCRISPR V2 purchased from

Addgene. LentiCRISPR V2 vector was digested with BsmBI and ligated with indicated
annealed oligonucleotides. Targeting sequence for RBMS3 is as the following:
CAGCTACATGGGCAAACGCC. Stable ESRP1 and ESRP2 knockout cells were
generated by lentiCas9-Blast purchased from Addgene. Targeting sequences for ESRP1
and ESRP2 are CTGGACCAAGCCCTCCGA and AGTCGGTCTCGTCCGAGCC,
respectively.
Anti-ESRP1 antibody (HPA023719) was from Sigma. Anti-ESRP2 antibody
(ab155227 and ab113486) was from Abcam. Anti-RBMS3 antibody (GTX47423) was
from Genetex. Antibodies against E-cadherin (14472), Snail (3879S), Twist (46702S),
Slug (9585S) and Vimentin (5741T) were from Cell Signaling. Anti-Smad2/3 antibody
was a sample from Santa Cruz. Anti-Smad2, Smad3 and Smad4 antibodies were sample
kit from Cell Signaling. Anti-β-actin antibody (MA5-15739) was from Thermo. AntiStrep-Tag antibody (2-1509-001) and Strep-Tactin XT Superflow 50% suspension (24010-002) were from IBA Life Science. Recombinant human TGF-β1 was purchased from
Peprotech (100-21). A8301 (SML0788) and actinomycin D (A1410) were purchased from
Sigma-Aldrich.
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Table 1 Primers for qPCR
Gene
SMAD2

Forward Primer
AGCAGGAATTGAGCCACAGAGT

Reverse Primer
AAGAGTAGTAGGAGATAGTTCT

SMAD3
SMAD4
SMAD7
CTGF
PAI1
ID2

ACCACTACCAGAGAGTAGAGA
ACTGCCAACTTTCCCAACATT
CCCCATCACCTTAGCCGACTCTGC
ACTGTCCCGGAGACAATGAC
ATTCAAGCAGCTATGGGATTCAA
TCAGCCTGCATCACCAGAGA

TGGGGCTCGATGCCTGCGGGGA
ACCAGTAAATCCATTCTGCTGCT
CCCAGGGGCCAGATAATTCGTTCC
TGCTCCTAAAGCCACACCTT
CTGGACGAAGATCGCGTCTG
CTGCAAGGACAGGATGCTGAT

MMP1
PTGS2
SOX2
BMI1

ATCGGGGCTTTGATGTACCC
AGTCCCTGAGCATCTACGGT
GGAGGAAGCTGACAACAATGAAA
TGCGAGCGCTGCACAT
TGCTGGAGAACTGGAAAGTG

GGCTGGACAGGATTTTGGGA
GCCTGCTTGTCTGGAACAAC
GGCCTGCACGAGGGTTT
TCATGAGCGTCTTGGTTTTCC
GATGAGGAGACTGCACTGGA

β-Actin

AGAGCTAGCTGCCTGAC

GGATGCCACAGGACTCCA

OCT4

3.3

Cell Viability Assay
This assay was performed essentially described by CellTiter-Glo 2.0 Manual. Briefly,

luminal cell lines (T47D and MCF7) were plated at a density of 20,000 cells per 96 well
plate (in triplicate) and allowed to grow for a specific time course. At desired time point,
add reagent equal to the volume of medium in each well. Allow mixing for 2 minutes on
orbital shaker and another 10 minutes of incubation at room temperature to induce cell lysis
and stabilization of signals. Luminescent signals were measured on Synergy HTX MultiMode Microplate Reader.

3.4

Transwell Migration and Invasion Assay
Cell were grown to 80% confluency, resuspended in serum-free medium and seeded

into the upper chamber of Transwell inserts with an 8 μm pore size membrane (Falcon) at
5x104 cells per insert. For the invasion assay, upper chambers of Transwell inserts were
pre-coated with 50 μL of Matrigel (BD Biosciences), which was allowed to dry for 1
hour prior to seeding of cells for invasion. The cells were allowed to migrate toward
DMEM/F12 supplemented with chemoattractant epidermal growth factor (EGF)
(20ng/mL) in the lower chamber. Basal-like MDA-MB-231 and BT-549 cell lines were
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incubated for 8 hours for migration assay and 24 hours for invasion assay. T47D and
MCF7 cells were incubated for 24 hours for migration assay and 48 hours for invasion
assay. At the end of incubation period, cells remaining in the upper side of the Transwell
insert membrane were mechanically removed using a cotton swab. The cells on the
bottom of the Transwell insert were washed twice with PBS, fixed with 4%
paraformaldehyde (2 minutes), methanol (10 minutes), washed once with PBS, and then
stained with 0.5% (w/v) crystal violet in 20% methanol (v/v) (10 minutes). The stained
cells in 4 non-overlapping fields from each insert were counted with an inverted
microscope, using the 20X objective (Eclipse TS100, Nikon Instruments, Melville, NY).
All experiments were performed in triplicates.

3.5

Colony formation Assay
Colony formation assay was performed using double-layer soft agar in 6-well plates

with a top layer of 0.35% agar and a bottom layer of 0.7% agar. Briefly, cells were
suspended in 0.35% agar medium and laid on the top of the supporting agar layer (0.7%
agar) in 6-well plates, and fed twice per week. Colonies were allowed to form in an
incubator at 37°C and 5% CO2 for 14 days. At the end of the incubation time, cell cultures
were photographed and the colonies were stained and counted.

3.6

Would Healing Assay
Cells for scratch assay were seeded at same density on 6-cm dish. At about 90%

confluency, cells were starved overnight. Next morning, a consistent wound (gap) was
created using pipette tip. After removal of cell debris with PBS, cells were replaced with
fresh medium and incubated for 24 hours. Gap measurement was performed by ImageJ
software. Migration rates were calculated using data from 10 measurements of random gap
points.

3.7

Mammosphere Assay
Mammosphere assay was performed following the protocol previously described

[138]. Briefly, cells were seeded in single-cell suspension in triplicates into ultra-low
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attachment 6-well plates (Corning) in DMEM/F12 medium supplemented with
20 ng/mL EGF, 5 mg/mL insulin, 0.5 mg/mL hydrocortisone and 2% B27. After 2 weeks
of incubation, the presence of spheres was assessed by inverted microscopy. At least 20
random fields for each cell lines were visualized; the number and size of spheres in the
20 fields were calculated as a percentage over that of parent cells.

3.8

3D On-top Matrigel Assay
This assay was performed following an established protocol. Essentially, pre-chilled

culture surface was coated with a thin layer of Matrigel. Single cell suspension was
subjected to centrifugation at ~115 g, resuspended in half the medium volume and plated
onto coated surface at 0.2x105 /cm2. A layer of 10% Matrigel (in medium) was added on
top to stabilize the cells and culture was maintained for 4 days.

3.9

Anchorage-independent Growth Assay
To observe the adhesion-independent growth of 14 luminal BC-derived clones,

0.8x103 cells were seeded in 96-well round bottom ultralow-attachment plates. Cells were
cultured for up to one week and photographs were taken daily.

3.10 RNA Isolation and Quantitative Real-Time PCR (qPCR)
Total RNA was prepared using the RNeasy Mini kit (Qiagen) according to the
manufacturer’s instructions. Specific quantitative real-time PCR experiments were
performed using SYBR Green Power Master Mix following manufacturer’s protocol
(Applied Biosystems). All values were normalized to the level of β-actin.

3.11 Immunofluorescence Staining and Western Blot Analysis
Experiments were performed as described previously [139, 140]. For
immunofluorescence staining, cells were grown on cover slips, fixed with 4%
paraformaldehyde and incubated overnight with anti-Strep-Tag primary antibodies.
Secondary antibodies were 568 goat anti-mouse IgG (H + L) (Molecular Probe, Carlsbad,
CA). Finally, cover slips were visualized under Nikon confocal microscope.
37

For Western blot analysis, cells were rinsed and collected on ice with cold PBS
by scraping. After centrifugation at 1000rpm for 3 minutes and removal of PBS, cell
pellet was lysed with lysis buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 0.2mM EDTA,
1% Triton-X100, 10% glycerol, 5mM β-glycerophosphate, 5mM 4NPP, 1mM Na3VO4,
5mM NaF, 2 μg/mL aprotinin, 1 μg/mL leupeptin and 0.5 tablet of protease inhibitor
cocktail). Cells were homogenized by gentle up-and-down pipetting and lysed for 10
minutes on ice followed by sonication for 1 minute. After high speed centrifugation for
15 minutes, supernatants were transferred in new tubes and protein levels were
quantified via Bradford assay followed by normalization. Sample buffer (4X) was added
at a ratio of 1:3 and proteins were then separated by SDS-PAGE gels, transferred to
PVDF or NC membrane and immunoblotted.

3.12 Crosslinking RNA Immunoprecipitation (CLIP)
This experiment was performed based on an established protocol. Cells were grown
on 15 cm dish and cultured to around 90% confluency. To crosslink in vivo, 37%
formaldehyde was added directly to cells in medium dropwise to a final concentration of
0.75% and incubated with gentle shaking for 10 minutes at room temperature. 125mM
glycine was then added for 5 minutes. Cells were rinsed and collected on ice with cold PBS
by scraping. After centrifuge at 1000rpm for 3 minutes, cell pellet was resuspended with
equal volume of polysome lysis buffer (100 mM KCl, 5 mM MgCl2, 10 mM HEPES pH7.0,
0.5% NP40, 1 mM DTT, 100 unit/mL RNase Out, 400 μM VRC, 10 μL protease inhibitor
cocktail) by gentle up-and-down pipetting. After high speed centrifuge for 15 minutes,
cell lysate was transferred to new tube and quantified for protein level. 20 μg lysate was
saved as RNA input at -20 °C for later use. Meanwhile, 100 μL Strep-Tactin beads were
washed twice with ice-cold NT2 buffer (50 mM Tris-HCl pH7.4, 150 mM NaCl, 1 mM
MgCl2, 0.05% NP40). After final wash, beads were resuspended in 850 μL ice-cold NT2
buffer supplemented with 200 units of RNase Out, 400 μM VRC, 1 μL of 1M DTT and
EDTA to 20 mM. For each RIP reaction, 2 mg cell lysate was added to the beads and
the total reaction volume was adjusted to 1 mL. Bead-lysate mixture was incubated on
rotation for 3 hours at 4 °C. Beads were pelleted by centrifuge at 2000rpm for 3 minutes
at 4 °C and washed four times with ice-cold NT2 buffer with rotation at 4 °C. Meanwhile,
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previously-collected cell lysate (RNA input tube) was thawed on ice. At final wash, 1/5
beads were collected for western blot analysis. After final wash, 1 mL Trizol reagent
(Invitrogen) was added directly to the beads and cell lysate (RNA input tube). RNA was
extracted following the manufacturer’s manual. 30 μg glycogen was added as a carrier
to aid in RNA precipitation. After cDNA synthesis, quantitative real-time PCR was
performed to determine the levels of desired transcripts. All equipment was kept at
RNase-free level and all reagents were prepared with RNase-DNase-free H2O.

3.13 Fluorescence-Activated Cell Sorting (FACS)
Cell Surface Marker Assay: Cells were detached from plates, blocked with 2%
BSA for 30 minutes and incubated with anti-human CD24 (PE-conjugated, ebioscience),
anti-human CD44 (PE-Cy7-conjugated, ebioscience), anti-human CD49f (PE-Cy7conjugated, ebioscience) or EPCAM and finally analyzed using FACSCalibur flow
cytometer.
Annexin Early-Apoptosis Assay: Experiment was performed essentially as
described by manufacture’s protocol using Annexin V-FITC Early Apoptosis Detection
Kit (Cell Signaling Technology). Briefly, MCF7 cells stably expressed control or
RBMS3 vector were treated with TGF-β1. 105-106 cells were detached from plates and
resuspended with ice-cold Annexin V binding buffer. 1 μL Annexin V-FITC conjugate
and 12.5 μL Propidium Iodide (PI) solution was added to 96 μL cell suspension. After
10 minutes of incubation on ice in the dark, cell suspension was diluted to a final volume
of 250 μl/assay with ice-cold Annexin V binding buffer. Analysis was performed
immediately using FACSCalibur flow cytometer.
Cell cycle analysis: The experiment was performed essentially as previously
described [141]. Briefly, cells were seeded and treated with TGF-β1 for 24 hours. Cells
were harvested and fixed in cold 70% ethanol at -20 °C for overnight. Cells were washed
with phosphate buffered saline (PBS) twice and stained by 50 μg/mL propidium iodide
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(PI) solution with 100 μg/mL RNase A in dark for 30 minutes. Cells were analyzed using
a FACSCalibur flow cytometer.
3.14 Drug Treatment
mRNA stability assay was accomplished by inhibition of global RNA synthesis
through the use of pharmacological inhibitor Actinomycin D (ActD). Cells were treated
with ActD at 5 ng/mL for 0, 3, 6 and 9 hours. At the end of incubation time point, medium
was removed and cells were directly lysed on dish with Trizol reagent.

3.15 Trypan Blue Exclusion Assay
This assay was performed to determine cell death. Briefly, cells were left untreated
or treated with TGF-β1 at 10 ng/mL for indicated periods of time. At the end of incubation
time point, all cells (both adherent and floating) were harvested, stained with trypan blue
and counted immediately to determine the percentage of nonviable cells (stained blue).
Columns represent the mean of three independent measurements and bars represent
standard error.

3.16 RNA-sequencing (RNA-seq)
Total RNAs isolated from T47D, T47D-RBMS3, T47D-ESRP1 KO, T47D-ESRP2
KO, T47D-ESRP DKO and T47D-ESRP DKO-RBMS3 cells using RNeasy Mini Kit
(Qiagen). RNA integrity and concentration were determined using Bioanalyzer (BioTek)
and agarose gel electrophoresis. The purified samples were sequenced and the clean reads
were mapped against human genome. The normalized expression values for each gene
were quantified using log2FPKM value (expected number of fragments per kilo base of
transcript sequence per million base pairs sequenced). The transcript levels of genes having
a fold change (FC) of greater than 0.5 were significantly differential between two samples.
The software Morpheus(https://software.broadinstitute.org/morpheus/) was used to draw
heatmap.
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3.17 Functional Enrichment Analysis for DEGs
DEG sets were screened out for functional enrichment analysis. Essentially, Gene
Ontology (GO) terms for biological processes, cellular components and molecular function
categories were annotated by two public resources: GO (http://geneontology.org/) and
Metascape (http://metascape.org/) [142-144]. Only terms with p-value <0.01 and the
number of enriched genes greater than 3 were considered as significant. All resultant terms
were then grouped into clusters based on their similarities. The most enriched term within
a cluster was chosen to represent the cluster. DEG sets were also used to conduct gene set
enrichment analysis (GSEA), which was performed with GSEA v3.0 on various functional
characteristic gene signatures.

Gene sets were obtained from Molecular Signature

Database (MSigDb).

3.18 Breast Cancer Survival Analysis
Kaplan-Meier survival analyses for clinical outcomes (RFS or DMFS) of breast
cancers were performed using web tool Kaplan-Meier Plotter (http://kmplot.com/analysis/)
and UCSC Xena tool (https://xenabrowser.net/). The percentiles of the patients between
the upper and lower quartile were auto-selected based on the best performing thresholds as
cutoffs.

3.19 Correlation analysis
Correlation analysis was analyzed with the Gene Expression Profiling Interactive
Analysis (GEPIA) online analysis tool, which uses the BRCA dataset from TCGA database
(http://gepia2.cancer-pku.cn/).
3.20 Human Breast Cancer Tissue Dataset Analysis
mRNA expression analysis of breast tumor datasets was conducted on web tool
Oncomine (https://www.oncomine.org/). Correlation analysis was analyzed with the Gene
Expression Profiling Interactive Analysis (GEPIA) online analysis tool, which uses the
BRCA dataset from TCGA database. (http://gepia2.cancer-pku.cn/).
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3.21 Statistical analysis
Experiments were repeated at least twice. Data are presented as mean ± SD. A
Student’s t-test (two tailed) was used to compare two groups. p < 0.05 was considered
statistically significant.
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CHAPTER 4. RESULTS
4.1

RBMS3 is correlated with malignance of breast cancer
To determine whether rbms3 mRNA expression is altered in breast cancer, we

interrogated gene expression datasets of human breast cancer samples from Oncomine
database. According to Turashvili and colleagues’ dataset, high level of rbms3 was found
in the invasive lobular breast carcinoma compared to ductal and lobular breast cells (Figure
4.1A). In Curtis dataset, 5 phyllodes tumor samples and 144 paired normal breast samples
were analyzed (Figure 4.1B). The mRNA expression of rbms3 was significantly increased
in phyllodes tumor samples when compared with normal controls. Interestingly, additional
analysis on Finak dataset of 53 breast tumor stroma samples and 6 normal breast stroma
samples revealed that the mRNA level of rbms3 was found significantly higher in the
invasive breast carcinoma stroma compared with normal breast stroma (Figure 4.1C). In
addition, rbms3 transcript was found to be to be absent in noninvasive luminal breast
cancer cell lines MCF7, T47D and SK-BR-3 (Figure 4.2). Our microarray dataset indicated
significant upregulation of rbms3 in the triple-negative breast cancer (TNBC) cells
compared with luminal BC MCF7 cells (Figure 4.3A). Based on gene expression profiles
from Cancer Cell Line Encyclopedia (CCLE) dataset, rbms3 was also markedly increased
in the BLBC cell lines (MDA-MB-157, MDA-MB-231, Hs578T and BT549) compared to
luminal breast cancer cell lines (MCF7, T47D and ZR-751) (Figure 4.3B). IHC staining
from the Human Protein Atlas database showed higher protein expression of RBMS3 in
myoepithelial cells as compared to ajacent luminal cells (Figure 4.4). Using UCSC Xena
online tool, we found that high expression of rbms3 predicts lower overall survival in 1273
samples from TCGA BRCA dataset (Figure 4.5A). Furthermore, Kaplan-Meier Plotter
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(KM Plotter) revealed that higher expression of rbms3 correlated with lower distant
metastasis free survival (DMFS) using microarray data from 1746 breast cancer samples
(Figure 4.5B). KM Plotter also predicted lower DMFS for low expression of rbms3 in 458
samples of grade 3 breast cancer patients (Figure 4.5C). Altogether, these data suggest that
RBMS3 correlates with breast cancer malignancy.
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Figure 4.1 Rbms3 is upregulated in invasive breast carcinoma
(A) Comparison of rbms3 mRNA expression between invasive breast tissue and normal
breast cells in Turashvili dataset (P<0.05). (B) Comparison of rbms3 mRNA expression
between normal breast cells and breast phyllodes tumor in Curtis dataset (P<0.001). (C)
Comparison of rbms3 mRNA expression between the stroma of invasive breast carcinoma
versus that of normal breast tissue in Finak dataset (P<0.05). Two-sample t-test was used
to compare rbms3 gene expression between carcinoma and normal samples. The
expression values were log2-transformed median-centered ratio. (data from Oncomine
database)
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Figure 4.2 Rbms3 is undetected in luminal and HER2+ subtype BC cell lines
Rbms3 mRNA in luminal MCF7 and T47D breast cancer cells, HER2-overexpressing SKBR-3 breast cancer cells, hTERT-HME1 normal breast cells and four fibroblast cell lines
(BJ, BJ hTERT+, fHDF/TERT166 and HBF TERT88) in the Human Protein Atlas database.
Expression quantification was shown as TPM (Transcripts Per Million). ND indicates no
transcripts detected.

Figure 4.3 Rbms3 is significantly increased in metastatic TNBC cell lines
(A) Analysis from microarray expression dataset contained 1 luminal (MCF7) and 4 triplenegative/basal-like (MDA-MB-157, MDA-MB-231, HS578T and BT549) breast cancer
cell lines.
(B) Analysis from CCLE expression dataset contained 3 luminal (MCF7, T47D and ZR751) and 4 triple-negative/basal-like (MDA-MB-157, MDA-MB-231, HS578T and BT549)
breast cancer cell lines.
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Figure 4.4 RBMS3 is found in the basal-like myoepithelial cells but not in adjacent
luminal cells
Representative IHC stain of RBMS3 in normal breast tissue from the Human Protein Atlas
database. Brown color stains for RBMS3 protein. Scale bar, 250 μm.
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Figure 4.5 Rbms3 is correlated with poor survival in BC patients
(A) Kaplan Meier plot of overall survival based on rbms3 gene expression in 1247 samples
from TCGA breast cancer (BRCA) dataset using UCSC Xena tool. Results were shown in
quartiles. p value < 0.05
(B)Kaplan Meier plot of distant metastasis-free survival based on rbms3 gene expression
in 1746 breast cancer patients. p value <0.05 [145]
(C) Kaplan Meier plot of distant metastasis-free survival based on rbms3 gene expression
in 458 breast cancer patients (grade 3). p value < 0.001 [145]
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4.2

RBMS3 induces cell migration, invasion, EMT and CSC traits
EMT program can impart several traits that are essential to the malignant

progression of carcinoma cells, including tumor-initiating properties, motility, the ability
to disseminate and increased tolerance to conventional chemotherapeutics [29, 146-148].
To investigate the functional effects of RBMS3, ectopic expression of RBMS3 was induced
in two luminal breast tumor cell lines, T47D and MCF7, which contain little or no
endogenous RBMS3. To study whether RBMS3 affects breast cancer cell viability, we
performed cell viability assay in MCF7 and T47D cells stably expressed control or RBMS3
vector. MCF7-RBMS3 and T47D-RBMS3 cells demonstrated minimal effect on cell
growth compared to control cells over the 96-hour interval examined (Figure 4.6A and B).
Next, we tested migration and invasiveness of these cells using Boyden chamber. RBMS3
expression markedly increased MCF7 cell migration and invasive capacity (Figure 4.7).
Similar results were also observed in T47D and MCF10A cells (data not shown). RBMS3
induced morphologic changes reminiscent of EMT, including downregulation of epithelial
marker CDH1 and upregulation of mesenchymal markers (TWIST1, TWIST2, SNAI1,
SNAI2, FOXC1 and FN1) in T47D cells. In addition, T47D-RBMS3 cells lost luminal
markers CD24 and gained expression of stem cell molecule Sox2 (Figure 4.8A). Similar
qPCR results were also seen in MCF7-RBMS3 cells (Figure 4.8B). Consistently, RBMS3
expression decreased the protein levels of epithelial marker E-cadherin, and induced the
protein levels of stem cell molecules (Sox2 and LSD1) in MCF7 and T47D cells (Figure
4.9). These data suggest RBMS3 is critical in controlling the expression of EMT and
pluripotency genes.
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Figure 4.6 RBMS3 has minimal effect on MCF7 or T47D cell growth
Graphic representation of cell growth rates by MCF7 (A) and T47D (B) cells stably
expressed RBMS3 or control vector. Cell viability was measured daily over a 4-day period.
Presented data are the mean ±SD from three independent experiments.

Figure 4.7 RBMB3 promotes MCF7 cell migration and invasion
Graphic representation of the invasiveness of T47D cells stably expressed control or
RBMS3 vector using a modified Boyden Chamber migration (A) or invasion (B) assay.
Quantification is shown in the right panel. Presented data are the mean ± SD from two
independent experiments in triplicates, with *** indicates p value < 0.001 when comparing
with control values. Scale bars, 100 μm.
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Figure 4.8 RBMS3 induces the mRNA levels of EMT and stem cell markers
(A-B) Real-time PCR analysis of the mRNA level of several EMT markers and stem cell
markers in T47D cells or MCF7 cells expressed control or RBMS3 vector. Data are shown
as mean ±SD from three independent experiments in triplicates.
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Figure 4.9 RBMS3 induces protein expression of EMT and stem cell markers
Western blot analysis of EMT marker (E-cadherin) and stem cell markers (Sox2 and LSD1)
in T47D and MCF7 cells stably expressed control or RBMS3 vector. GAPDH was loaded
for normalization.
4.3

RBMS3 promotes cancer stem cell (CSC)-like characteristics
Cancer cells that develop the ability to undergo EMT lose anchorage dependence

and thus can detach from the primary tumor. Soft-agar assay was performed in T47D cells
to determine whether RBMS3 affects anchorage-dependent growth of these cells. RBMS3
expression resulted in ~ two-fold increase and ~ five-fold increase in the number of softagar colonies in T47D and MCF7 cells, respectively (Figure 4.10). Tumorsphere formation
is largely dependent upon the self-renewal and tumorigenic abilities of stem/progenitor
cells, known as cancer stem cells (CSCs), to survive and growth in serum-free suspension.
Cells are grown in serum-free, non-adherent conditions in order to CSC/progenitor cells
since only CSC/progenitor cells can survive and proliferate under such environment . CSCs
is known as the main reason for cancer recurrence, metastasis and therpeutic resistance
[149]. To study the role of RBMS3 in tumorsphere formation, we cultured MCF7 cells
expressed control or RBMS3 vector in serum-free suspension medium for two weeks and
then examined tumorsphere formation of these cells by looking at their size and density.
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MCF7 control cells formed moderate numbers of mammospheres with similar average
sizes (30-100 μm). Surprisingly, MCF7-RBMS3 cells appeared to form mammospheres of
varying sizes. Quantification of tumorsphere counts suggested that while RBMS3
expression led to moderate decrease in mammospheres of sizes above 30µm, it also led to
dramatic increase in small irregular cell aggregates/clusters below 30 μm (not strictly
consider as tumorsphere) or even mini cell clusters (Figure 4.11). Formation of varying
sizes of mammospheres, especially those mini clusters, is particularly favorable for tumor
cell dissemination in the circulation. Similar results were also observed in T47D-RBMS3
cells (data not shown). These results, together with qPCR and western blot results, indicate
that RBMS3 may enhance CSC-like properties in luminal breast cancer cells.
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Figure 4.10 RBMS3 promotes colony formation in MCF7 and T47D cells
Data of colony formation assay are presented as a percentage of vector control cell lines.
Data are shown as mean ±SD in two independent experiments in triplicates. (***p < 0.001)
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Figure 4.11 RBMS3 promotes tumorsphere formation in BC cells
(A) Tumorsphere formation was assessed in MCF7 cells stably expressed control or
RBMS3 vector. Representative images of tumorspheres are shown. Scale bars, 1000 μm.
(B) Data of tumorsphere formation assay are presented as counts (size over 30 μm) or
folds of control vector values (size between 10-30 μm), with mean ± SD of two
independent experiments performed in triplicates (***p < 0.001).
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4.4

Loss of RBMS3 Suppresses EMT and CSC population
To further explore the function of RBMS3 in TNBC cells, we established stable

RBMS3-knockout clones in BT-549, Hs578T, MDA-MB-157 and MDA-MB-231 cells by
CRISPR/Cas9 technique. BT-549 cells appeared with stellate projections, whereas BT549RBMS3 KO cells exhibited a marked change in morphology, with rounded/polygonal
shape when cultured at low density (Figure 4.12). To investigate whether RBMS3 affects
breast cancer cell growth, we measured cell growth rates in BT-549 cells by cell viability
assay. Over the time course examined, RBMS3 knockout demonstrated significant
decrease on cell growth in BT-549 cells (Figure 4.13). We also measured cell growth in
Hs578T cells by cell counting. Knockout of RBMS3 resulted in significant decrease in
growth rate in Hs578T cells (Figure 4.14). To investigate the migratory ability mediated
by RBMS3 in TNBC cells, transwell assay was performed BT-549 and MDA-MB-157
cells. Indeed, loss of RBMS3 significantly inhibited cell migration (Figure 4.15). This
finding was supported by in vitro wound healing assay in MDA-MB-231 cells. Closure of
the scratch wound required significantly longer time in RBMS3-depleted cells than in
control cells. Statistical analysis indicated that migratory activity of RBMS3-depleted cells
was 60% lower than that of control cells (Figure 4.16). Loss of RBMS3 led to significant
upregulation of epithelial markers (CDH1 and FOXA1) and downregulation of several
mesenchymal markers (SNAI2, TWIST1, TWIST2, CDH2, FN1 and FOXC1) in BT549 cells
(Figure 4.17). Importantly, RBMS3 depletion reduced the protein levels of epithelial
marker E-cadherin, while increased the protein levels of mesenchymal markers (Slug,
Twist, Vimentin, Snail and N-cadherin) in BT549 and MDA-MB-157 cells, as confirmed
by western blotting (Figure 4.18). To test whether RBMS3 affected CSC characteristics,
BT549 control and RBMS3 knockout cells were subjected to FACS analysis using
CD44high/CD24low

and

CD49fhigh/CD24low/EpCAM+

as

surface

markers.

The

CD44high/CD24low and CD49fhigh/CD24low/EpCAM+ CSC populations (represented by the
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upper left quadrant) were both dramatically decreased in RBMS3-depleted cells vs. control
cells, confirming that RBMS3 positively regulates CSC traits (Figure 4.19). Altogether,
the above findings further support the role of RBMS3 as a crucial factor in promoting breast
cancer cell migration, invasion, EMT as well as CSC characteristics.

Figure 4.12 Loss of RBMS3 reduces mesenchymal phenotype in BT549 cells
Representative images of BT549 cells with or without loss of RBMS3. At low cell density,
BT549 cells exhibit elongated spindle-like shape, whereas RBMS3 KO cells show
shortened, polygonal and spread-out shape. Scale bars, 400 μm.
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Figure 4.13 Loss of RBMS3 significantly inhibits BT549 cell viability
Graphic representation of cell viability in BT549 cells with or without loss of RBMS3
over a 3-day period measured by CellTiter-Glo 2.0 Assay. Presented data are the mean
±SD from three independent experiments. (*p < 0.05)

Figure 4.14 Loss of RBMS3 significantly decreases Hs578T cell growth
Graphic representation of cell growth rates in Hs578T cells with or without loss of
RBMS3 over a 3-day period measured by cell counting. Presented data are the mean ±
SD from three independent experiments. (*p < 0.05)
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Figure 4.15 Loss of RBMS3 inhibits BT-549 and MDA-MB-157 cell migration
Graphic representation of the invasiveness of MDA-MB-157 and BT-549 cells with or
without loss of RBMS3 using a modified Boyden Chamber migration assay. Quantification
is shown in the right panel. Presented data are the mean ± SD from two independent
experiments in triplicates, with ** indicates p value < 0.01, *p <0.05 when comparing with
control values. Scale bars, 100 μm.
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Figure 4.16 Loss of RBMS3 prevents wound closure in MDA-MB-231 cells
Representative images of scratch assay in MDA-MB-231 cells with or without loss of
RBMS3. Distance of wound closure was measured at 0 and 24h. Red dashed lines show
the margins of migrating cells. Scale bars, 1000 μm. (G) Western blot analysis of RBMS3
knockout in MDA-MB-231 cells and statistical analysis of 10 random measurements of
scratch assay. (***p < 0.001) (H) Migratory ability of MDA-MB-231 and BT549 cells
and the corresponding RBMS3 knockout cells were analyzed by transwell migration
assay. Scale bars, 200 μm. (I) Invasive ability of MDA-MB-231 and BT549 cells and
the corresponding RBMS3 knockout cells were analyzed by transwell invasion assay.
Scale bars, 200 μm.

60

Figure 4.17 Loss of RBMS3 reduces mesenchymal markers and increases epithelial
markers at mRNA level
Real-time PCR analysis of the mRNA level of several mesenchymal markers (SNAI1,
SNAI2, TWIST1, TWIST2, CDH2, FN1, FOXC1) and epithelial markers (CDH1, FOXA1)
in BT549 cells with or without loss of RBMS3. Data are shown as mean ± SD from two
independent experiments in triplicates. (*p < 0.05, **p < 0.01, *** < 0.001, NS = not
significant)
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Figure 4.18 Loss of RBMS3 reduces mesenchymal markers and increases epithelial
markers at protein level
Western blot analysis of EMT markers in BT549 and MDA-MB-157 cells with or without
loss of RBMS3. β-actin was loaded as control.
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Figure
4.19
Loss
of
RBMS3
reduces
CD44high/CD24low
and
high
low
+
CD49f /CD24 /EpCAM CSC populations
Representative FACS images from BT549 cells with or without loss of RBMS3 using
CD44high/CD24low or CD49fhigh/CD24low/EpCAM+ as surface markers. Quantification of
CSC populations are shown in the right panel; Presented data are the mean ±SD from three
experiments. (***p < 0.001)
4.5

RBMS3 is correlated with TGF-β Signaling
To further investigate the molecular mechanism of RBMS3 involved in the

metastasis of breast cancer, T47D cells expressed control or RBMS3 vector were selected
for RNA-seq analysis to screen for potential targets of metastasis. GO biological analysis
of deregulated genes (DEGs) between RBMS3 vs. control list revealed top 20 significant
pathways, including genes encoding ECM-associated proteins, GPCR ligand binding and
chemotaxis-associated proteins, etc. (Figure 4.20). A subset of enriched terms was selected
for network plot (Figure 4.21) and protein-protein interaction networks were shown using
Metascape platform (Figure 4.22-23 and Table 2). Table 3 shows a list of top 20 DEGs
discovered in the RNA-seq dataset. Gene set enrichment analysis (GSEA) indicated an
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enrichment of pathway of EMT, inflammatory response, hypoxia and TGF-β signaling in
T47D-RBMS3 cells compared with T47D control cells (Figure 4.24). In addition, positive
correlation between RBMS3 and apical junction pathway as well as other pathways was
also found in T47D-RBMS3 cells (Table 4). Significant correlation of RBMS3 with EMT
and TGF-β signatures was also observed in the BRCA dataset from TCGA database using
GEPIA2 online analysis tool (Figure 4.25). A8301 prevents phosphorylation of Smad2/3,
leading to decreased Smad-dependent TGF-β signaling. TGF-β1 treatment inhibited the
expression of its downstream target CTGF in T47D cells, which was potentiated by Alk5
inhibitor A8301, suggesting that TGF-β1-mediated downregulation of CTGF is mediated
mainly through non-Smad pathways. Overexpression of RBMS3 in T47D cells led to
significantly downregulated CTGF expression, which was enhanced by TGF-β1 treatment.
A8301 treatment, however, failed to reverse downregulation of CTGF, indicating that
RBMS3-mediated CTGF downregulation was mainly regulated through non-Smad
pathways (Figure 4.26). We also noticed that overexpression RBMS3 facilitated TGF-β1mediated downregulation of E-cadherin in MCF7 cells (Figure 4.27).
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Figure 4.20 Functional enrichment analysis of deregulated gene set (DEGs)
The DEG list of T47D-RBMS3 cells (vs. T47D control) was subjected to enrichment
analysis using Gene Ontology (GO) terms for biological processes, cellular components
and molecular function categories annotated by Gene Ontology. Data represented as fold
enrichment.

Figure 4.21 Heatmap for GO analysis of DEGs showing top 20 significant pathways
The DEG list of T47D-RBMS3 cells (vs. T47D control) was subjected to pathway and
process enrichment analysis with ontology sources: Kyoto Encyclopedia of Genes and
Genomes (KEGG) Pathway, GO Biological Processes Reactome Gene Sets, Canonical
Pathways and CORUM. All genes in the genome were included as the enrichment
background. P-value was calculated based on accumulative hypergeometric distribution.
Enrichment factor is the ratio between the observed counts and the counts expected by
chance. Terms with a p-value < 0.01, a minimum count of 3, and enrichment factor > 1.5
are collected and grouped into clusters based on their similarities. The most statistically
significant term within a cluster is chosen to represent the cluster. p<0.05
(http://metascape.org/)
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Figure 4.22 Network of Enriched Terms
To further capture the relationships between the terms, a subset of enriched terms was
selected as a network plot, where terms with a similarity > 0.3 was connected by edges.
The terms with the best p-value from each of the 20 clusters, with constraints that no more
than 15 terms per cluster and no more than 250 terms in total, were selected to be visualized.
Each node represents an enriched term and is colored by its cluster ID or p-value. a) colored
by cluster ID, where nodes that share the same cluster ID are typically close to each other;
b) colored by p-value, where terms containing more genes tend to have a more significant
p-value. Results displayed in ‘cose’ layout format. (http://metascape.org/)
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Figure 4.23 Protein-protein Interaction Network and MCODE Components
Protein-protein interaction enrichment analysis was carried out in the DEG list of T47DRBMS3 cells vs. control cells via the Metascape platform, which utilizes the following
databases: BioGrid, InWeb_IM and OmniPath. This network plot contains the subset of
proteins that form physical interactions with at least one other member in the list. The
Molecular Complex Detection (MCODE) algorithm has been applied to identify and
assemble network components for individual gene lists. Pathway and process enrichment
analysis was applied to each MCODE component independently, and 2-3 best-scoring
terms by p-value are retained as functional description of the corresponding components,
shown in Table 3.

Table 2 Protein-protein interaction network and MCODE components identified in
the DEG list of T47D-RBMS3 vs. T47D cells
Color
MCODE
GO
Description
Log10(P)
MCODE_1 R-HSA-418594
G alpha (i) signaling events
-39.3
MCODE_1

R-HSA-373076

Class A/1 (Rhodopsin-like
receptors)

-32.6

MCODE_1

R-HSA-500792

GPCR ligand binding

-32.3

MCODE_2

R-HSA2262752

Cellular responses to stress

-13.3
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MCODE_2

R-HSA8953897

Cellular responses to external
stimuli

-12.4

MCODE_2

hsa05322

Systemic lupus erythematosus

-11.6

MCODE_3

R-HSA-416476

G alpha (q) signaling events

-28.8

MCODE_3

R-HSA-373076

Class A/1 (Rhodopsin-like
receptors)

-26.3

MCODE_3

R-HSA-500792

GPCR ligand binding

-24.2

MCODE_4

R-HSA-418555

G alpha (s) signaling events

-13.2

MCODE_4

R-HSA-500792

GPCR ligand binding

-11.2

MCODE_4

GO:0008277

regulation of G protein-coupled
receptor signaling pathway

-9.3

MCODE_6

GO:0006790

sulfur compound metabolic
process

-8.3

MCODE_6

GO:0005975

carbohydrate metabolic process

-7.2

MCODE_6

GO:1901137

carbohydrate derivative
biosynthetic process

-6.7

MCODE_7

hsa05217

Basal cell carcinoma

-9.9

MCODE_7

R-HSA-195721

Signaling by WNT

-9.3

MCODE_7

GO:0060070

canonical Wnt signaling
pathway

-9.3

MCODE_8

R-HSA-211897

Cytochrome P450 - arranged by
substrate type

-12.9

MCODE_8

R-HSA-211945

Phase I - Functionalization of
compounds

-11.8

MCODE_8

R-HSA-211859

Biological oxidations

-10.2

MCODE_9

R-HSA3928665

EPH-ephrin mediated repulsion
of cells

-10.8

MCODE_9

GO:0048013

ephrin receptor signaling
pathway

-9.8

MCODE_9

R-HSA2682334

EPH-Ephrin signaling

-9.7
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MCODE_12

R-HSA-983168

Antigen processing:
Ubiquitination & Proteasome
degradation

-5.7

MCODE_12

GO:0000209

protein polyubiquitination

-5.7

MCODE_12

R-HSA-983169

Class I MHC mediated antigen
processing & presentation

-5.4

MCODE_13

R-HSA8856825

Cargo recognition for clathrinmediated endocytosis

-7.1

MCODE_13

R-HSA8856828

Clathrin-mediated endocytosis

-6.7

MCODE_13

R-HSA-199991

Membrane Trafficking

-4.7

MCODE_17

GO:0016584

nucleosome positioning

-9.5

MCODE_17

GO:0031936

negative regulation of chromatin
silencing

-9.3

MCODE_17

GO:0031935

regulation of chromatin
silencing

-8.4

MCODE_18

M3008

NABA ECM
GLYCOPROTEINS

-6.3

MCODE_18

M5884

NABA CORE MATRISOME

-5.8

MCODE_19

GO:0046580

negative regulation of Ras
protein signal transduction

-8.1

MCODE_19

GO:0051058

negative regulation of small
GTPase mediated signal
transduction

-7.9

MCODE_19

R-HSA6802949

Signaling by RAS mutants

-7.8
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Table 3 List of the top 20 DEGs in T47D-RBMS3 vs. T47D cells from RNA-seq
expression dataset.
Genes
Upregulated (FC)
Genes
Downregulated (FC)
RP11-9J18.1
3.626461
KRT16
-4.216279341
ANGPT1

3.269688

GREM2

-3.176657388

CLDN16

3.126702

HIST1H4D

-2.662753541

CRABP1

2.870269

CLEC3A

-2.479534141

GALNT5

2.759951

HPSE2

-2.350982455

CLDN1

2.484171

LA16c-312E8.5

-2.326493157

HBA1

2.387961

HIST1H1B

-2.135837845

LDHB

2.342741

TNFRSF11A

-2.0021068

FAM25A

2.103505

OR52E6

-1.908076923

EPHA6

2.062273

LMO4

-1.875299924
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Figure 4.24 GSEA showing an enrichment of several pathways
Gene Set Enrichment Analysis (GSEA) showing an enrichment of the following pathways
using DEG list of T47D-RBMS3 versus T47D control cells: EMT, inflammatory response,
apical junction, hypoxia and TGFβ-related gene signatures. NES indicates normalized
enrichment score.
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Table 4 Selected pathways from GSEA analysis with highest ranked NES (>1.00)
indicating high probability of positive correlation.
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Figure 4.25 Correlation of RBMS3 and EMT/ TGFβ-related gene signatures
Correlation analysis was performed on the Gene Expression Profiling Interactive Analysis
version 2 (GEPIA2) online analysis tool, which analyzes BRCA dataset from TCGA
database. R denotes correlation efficient. TPM, transcript per million. a) Correlation
between RBMS3 and seven EMT signatures (SNAI1, SNAI2, TWIST1, TWIST2, ZEB1,
ZEB2, VIM). b) Correlation between RBMS3 and five TGFβ pathway component
signatures (TGFBR1, TGFBR2, SMAD2, SMAD3 and SMAD4). c) Correlation between
RBMS3 and four TGFβ pathway targets (PTGS2, CTGF, SMAD7 and SNAI2).
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Figure 4.26 RBMS3 promotes downregulation of TGF-β1-regulated CTGF gene
expression in T47D cells
Real-time PCR analysis of TGF-β downstream gene CTGF level in T47D cells stably
expressed RBMS3 or control vector treated with TGF-β1 (10 ng/mL) or TGFβR1 inhibitor
A8301 (5 μM). Data are shown as mean ± SD from two independent experiments in
triplicates.

Figure 4.27 RBMS3 facilitates TGF-β1-mediated downregulation of E-cadherin
Representative immunofluorescence images of MCF7 cells stably expressing RBMS3 or
control vector left untreated or treated with TGF-β1 (10 ng/mL) for 24 hours, and then
immunostained with anti-E-cadherin antibody and DAPI. Scale bars, 40 μm.
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4.6

RBMS3 alleviates TGF-β1-mediated cytostasis and apoptosis in luminal breast
cancer cells
TGF-β signaling features a growth inhibitory effect at premalignant stages of breast

cancer cells, but aggressive oncogenic activities at advanced malignant state [54, 150].
Long term treatment (~two weeks) of TGF-β1 induced massive cell death in MCF7 cells,
but exerted significantly lower impact on MCF7-RBMS3 cells (Figure 4.28). Since
RBMS3 posed little impact on MCF7 cell proliferation (Figure 4.6A), this data indicated
the possibility of RBMS3 in suppressing TGF-β1-induced cell death. To confirm this data,
MCF7 control and RBMS3-expressing cells were subjected to trypan blue exclusion assay.
MCF7-RBMS3 cells showed significantly reduced dead cells compared to control cells
starting at day 3 post treatment of TGF-β1 (Figure 4.29). To determine whether apoptosis
is the cause of cell death induced by TGF-β1, cells were examined for biochemical and
morphological markers of apoptosis using Propidium Iodide/Annexin V staining. After 24
hour TGF-β1 treatment, MCF7-RBMS3 and control cells showed similar baseline
apoptotic population of 0.6% (data not shown). However, after 72 hours, TGF-β1 induced
a drastic increase in the apoptotic cell population to 54.3% in control cells versus 36.7% in
MCF7-RBMS3 cells (Figure 4.30). To study the effect of RBMS3 on the TGF-β1-mediated
cytostatic effect on MCF7 cells, we examined cell cycle distribution after 24 hour TGF-β1
treatment. TGF-β1 induced an increase in the fraction of S phase cells and decrease in the
fraction of G2/M phase MCF7 cells. Upon TGF-β1 stimulation, compared to MCF7 control
cells, MCF7-RBMS3 showed significantly higher fraction of S phase cells and lower
fraction of G0/G1 phase cells, suggesting that more cells entered into S phase and that
RBMS3 seems to prevent the TGF-β1-mediated G1-S phase arrest (Figure 4.31). Upon 24
hours of TGF-β1 stimulation, MCF7 control cells showed upregulation of pro-apoptotic
proteins Bad and cleaved Caspase 3, and downregulation of cell cycle protein CDC2
compared to untreated cells, suggesting increased apoptosis and decreased proliferation in
the TGF-β1-treated MCF7 cells. Upon TGF-β1 stimulation, however, MCF7-RBMS3 cells
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showed a reduction in pro-apoptotic protein Bax and unchanged levels of Bad, cleaved
Caspase 3 and CDC2 compared to untreated cells, suggesting decreased apoptosis and
unaffected proliferation in these cells (Figure 4.32). These data suggest that RBMS3 may
alleviate TGF-β1-mediated apoptotic and cytostatic effects on MCF7 cells.

Figure 4.28 RBMS3 suppresses TGF-β1-induced apoptosis in MCF7 cells
Representative images of MCF7 cells stably expressed control or RBMS3 vector followed
by administration of EGF (10 ng/mL) and TGF-β1 (10 ng/mL) for two weeks. Relative
viability is measured by cell counting and data are plotted using untreated MCF7 cells as
control. Scale bars, 400 μm. Data are shown as mean ± SD from three independent
experiments. *** p < 0.001 when TGF-β1-treated MCF7-RBMS3 group is compared with
TGF-β1-treated MCF7 group.
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Figure 4.29 RBMS3 prevents TGF-β1-induced cell death in MCF7 cells
Cells were treated with TGF-β (10 ng/mL) for indicated period of time, typsinized and
counted for nonviable cells with trypan blue. Data were represented as mean ± SD from
three independent experiments. (NS indicates nonsignificant, * indicates p <0.05)
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Figure 4.30 Annexin V/PI staining of MCF7-RBMS3 cells treated with TGF-β1
(A) Representative FACS images from MCF-7 cells expressed control or RBMS3 vector
with TGF-β1 treatment for 72 hours using Annexin V-FITC Early Apoptosis Detection Kit.
Annexin V-FITC conjugated protein binds to cell surfaces expressing phosphatidylserine,
an early apoptosis marker. Cells stained with propidium iodide (PI), a non-cell-permeable
DNA dye, indicate necrotic cells. Cells stained with both Annexin V-FITC and PI
demonstrate late stage apoptosis and early necrosis.
(B) Quantification of apoptotic population between MCF-7 cells expressed control or
RBMS3 vector under TGF-β1 treatment is shown. Data are shown as mean ±SD from two
independent experiments. ***p value < 0.005
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Figure 4.31 RBMS3 facilitates TGF-β1-mediated increase of S-phase population
Statistical analysis of Cell cycle distribution (G0/G1 phase, S phase or G2/M phase) of
MCF7 cells stably expressed RBMS3 or control vector. Cells were starved overnight and
then left untreated or treated with TGF-β1 for 24 hours.
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Figure 4.32 RBMS3 regulates TGF-β1-mediated apoptosis and cell cycle markers
Western blot analysis of apoptosis regulators (Bax, Bad, cleaved Caspase 3 and Bcl2) and
cell cycle regulators (CDC2, CDK2, p21 and p27) in MCF7 cells stably expressed control
or RBMS3 vector in the presence or absence of TGF-β1 (10 ng/mL) for 24 hours. α-tubulin
was loaded as control.
4.7

Loss of RBMS3 Disrupts Smad-dependent TGF-β Signaling
On the other front, RBMS3 depletion significantly downregulated TGF-β effectors

Smad2 and Smad3 (Figure 4.33). Furthermore, loss of RBMS3 suppressed TGF-βregulated genes (Figure 4.34). Of note, CTGF and PTGS2 are recognized to be drivers of
breast cancer bone metastasis [151]. RBMS3 depletion led to significant decreases in the
total level of Smad2, Smad3 and Smad4 protein and the phosphorylation level of Smad2
and Smad3 in BT549 cells. We also noticed that EMT transcription factors Snail, Slug and
Twist are significantly reduced upon loss of RBMS3 (Figure 4.35). These data further
confirm that RBMS3 is involved in TGF-β-mediated EMT.
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Figure 4.33 Loss of RBMS3 downregulates Smad2 and Smad3
Real-time PCR analysis of the mRNA expression of TGF-β signaling mediators Smad2,
Smad3 and Smad4 in BT549 cells with or without loss of RBMS3. ***p <0.001 and NS
stands for statistically non-significant. Data are shown as mean ± SD from three
independent experiments in triplicates.
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Figure 4.34 Loss of RBMS3 downregulates TGFβ1-regulated genes
Real-time PCR analysis of TGF-β downstream gene PAI1, CTGF, ID2, PTGS2 and Smad7
levels in BT549 cells with or without loss of RBMS3 treated with TGF-β1 for 0, 2, 4, 8
hours. Data are shown as mean ±SD from three independent experiments in triplicates.
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Figure 4.35 Loss of RBMS3 reduces TGF-β1 effector Smad proteins and EMT
transcription factors
Western blot analysis of TGF-β signaling mediators (Smad2, p-Smad2, Smad3, p-Smad3
and Smad4) and mesenchymal markers (Slug, Twist, Snail) in BT549 cells with or
without loss of RBMS3 left untreated or treated with TGF-β1 at 10 ng/mL. GAPDH was
loaded for normalization.

4.8

RBMS3 regulates TGF-β signaling by stabilizing Smad transcripts
Once activated by TGF-β ligands, TGF-β signaling is mediated through Smad and

non-Smad pathways to regulate transcription, translation, post-translational modifications,
protein synthesis and RNA biogenesis [56]. In the canonical TGF-β pathway, TGF-β ligand
binds to the type 2 TGF-β receptor (TGFBR2), which recruits the TGFBR1. The receptors
dimerize and undergo autophosphorylation, allowing for the recruitment and
phosphorylation of Smad2/3 by TGFBR1. The activated Smad2/3 dissociate from the
plasma membrane, hetero-oligomerize with Smad4 and translocate into the nucleus to
mediate gene expression/repression. Since protein levels changes of Smad2/3 were
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observed in cells transfected with CRISPR/Cas9-RBMS3 or ectopic RBMS3 in
comparison with mock-treated controls, we asked whether RBMS3 regulates Smad2/3
transcripts. To test this possibility, we first examined the subcellular localization of
RBMS3. As expected, we found that RBMS3 was mainly localized in the cytoplasm,
suggesting roles in RNA metabolism (Figure 4.36). Next, we asked whether RBMS3
physically interact with Smad2/3 transcripts. Lentiviral vectors of strep-tagged full-length
RBMS3 (RBMS3-Strep) and strep-tagged mutant RBMS3 lacking the two putative RNAbinding domains (dRRM-RBMS3-Strep) were generated, respectively (Figure 4.37A).
RNA immunoprecipitation assay followed by RT-PCR was performed using cell extracts
from MDA-MB-231 cells that were induced to express RBMS3-Strep or dRRM-RBMS3Strep (Figure 4.37B). We found significant enrichment of Smad2/3 transcripts in MDAMB-231 cells expressing RBMS3-Strep compared to dRRM-RBMS3-Strep, indicating
physical interaction between RBMS3 and Smad2/3 transcripts (Figure 4.38). RNA-binding
proteins are known to regulate gene expression at post-transcriptional levels, including
mRNA stability. In zebrafish prechondrogenic crest cells, RBMS3 may regulate the
stability of Smad2 transcript to control the pool of protein available for signaling [136]. To
explore whether this mechanism applies to TNBC cells, the mRNA stability of Smad
transcripts was measured. Upon treatment with transcription inhibitor actinomycin D (5
μg/ml), knockout of RBMS3 significantly decreased the half-lives of Smad2/3/4 transcripts
in BT-549 cells (Figure 4.39). Altogether, our results suggest that RBMS3 posttranscriptionally modulates TGF-β signaling by stabilizing Smad2/3/4 mRNAs.
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Figure 4.36 RBMS3 is mainly localized in the cytoplasm
Representative immunofluorescence images of MDA-MB-231 cells stably expressed
control or Strep-RBMS3 vector immunostained by anti-Strep antibody, visualized by goat
anti-mouse conjugated with Alexa fluor 568 under confocal microscope.
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Figure 4.37 Schematic of constructs and RNA-Immunoprecipitation Procedure
(A)Graphic representation of FL-RBMS3-Strep (full length) and dRRM-RBMS3-Strep
(RRM motif-deficient) constructs. RRM denotes RNA recognition motif (RRM). Numbers
of amino acids denote the start and end of each protein segment or motif.
(B) Graphic representation of general RNA-Immunoprecipitation workflow. Detailed
protocol is described in Materials and Methods Chapter below.
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Figure 4.38 RNA-Immunoprecipitation assay showing enrichment of Smad2/3/4
transcripts
Real-time PCR analysis of Smad transcripts enriched (fivefold as cutoff, red dashed line)
for RBMS3-Strep (n=3 experiments). Data are shown as mean ± SD from three
independent experiments. Other transcripts that are insignificantly enriched are not shown
here.
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Figure 4.39 RBMS3 regulates Smad2/3/4 mRNA stability
Real-time PCR analysis of remaining Smad transcripts (normalized to the level of actin
transcript) in BT549 cells with or without RBMS3, and plotted along with time after
Actinomycin D (5 μg/mL) treatment. T1/2 represents relative half-life of the specific Smad
mRNA in the presence or absence of RBMS3.
4.9

RBMS3 is negatively correlated with ESRPs expression
Luminal BC cells are well-known to be rather difficult to become metastatic,

largely due to presence of intrinsic master regulators that govern the identity of the cell
type. ESRP1 and ESRP2 (ESRP1/2) are splicing regulators that govern epithelial isoforms
of proteins during mammalian development. ESRP1/2 are essential for a range of epithelial
cell properties, such as cytoskeletal dynamics, cell motility, cell-cell junctions and
pathways involved in EMT [152]. Importantly, loss of ESRP1 and ESRP2 disrupts the
ability to form a proper epithelial layer, concomitant with increased motility and expression
of invasive markers, suggestive of acquisition of mesenchymal phenotypes. Therefore,
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ESRPs are known to suppress EMT in various cancers. Our microarray dataset suggested
Esrp1 and Esrp2 are overexpressed in luminal BC cells but repressed in BLBC cells, which
is consistent with western blotting results (Figure 4.40-42). While ESRP1 contains 4
RRMs, a DnaQ-like 3’-5’ exonuclease domain superfamily (DEDD) and a Domain of
Unknown Function (DUF), ESRP2 contains 3 RRMs and a DEDD (Figure 4.43). To better
understand the roles of ESRPs and RBMS3, we generated stable ESRP knockout clones
and RBMS3 overexpression clones and subjected them to functional assays and RNA-seq.
Western blotting suggested successful establishment of these clones (Figure 4.44-45). By
appearance, T47D-ESRP1 KO cells are more stretched and edged, whereas T47D-ESRP2
KO cells appear more rounded and organized than control cells. T47D-ESRP DKO cells
attach loosely to dishes, instead, they tend to aggregate to form clusters or grow on stacks.
Surprisingly, T47D-ESRP DKO-RBMS3 cells regains the ability to attach to dishes, an
indication that RBMS3 is involved in cell adhesion and spreading. None of the cell lines
showed a typical mesenchymal appearance of a spindle-like shape, even in the presence of
TGF-β (Figure 4.46). Despite of this, we asked whether RBMS3 contribute to the EMT
process by ectopically expressing an EMT transcription factor Slug in each of the T47Dderived clones. Indeed, at day 9 post transfection, we noticed that Slug overexpression in
T47D-ESRP DKO-RBMS3 cells resulted in ~ 12-fold increase in spindle-like shaped cells
than Cas-9 expressing control cells, compared to the 3 ~ 4 fold increase in cells with loss
of ESRP1/2 or RBMS3 expression (Figure 4.47). This suggests that RBMS3 may
predispose the cells to a state that is prone to EMT. Moreover, long term expression (over
10 days) of EMT transcription factors Slug or Snail led to significant apoptosis in T47D
cells with or without loss of ESRP1 or ESRP2. Overexpression of Twist in T47D cells
with or without loss of ESRP1 also induced apoptosis, but not in cells with loss of
ESRP2. Interestingly, loss of both ESRPs almost completely abolished apoptosis
mediated by Slug, Snail or Twist (data not shown). The effects of TGF-β, Snail, Slug and
Twist on the apoptosis and appearance of these cells lines are summarized in Table 5.
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Figure 4.40 Rbms3 is inversely correlated with ESRP1 and ESRP2 in TNBC cells
compared to luminal BC cells (RNA-seq)
Data from CCLE RNA-seq expression dataset contained 3 luminal (MCF7, T47D and ZR751) and 4 basal-like/triple negative (MDA-MB-157, MDA-MB-231, Hs578T and BT549)
BC cell lines.
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Figure 4.41 Rbms3 is inversely correlated with ESRP1 and ESRP2 in TNBC cells
compared to luminal BC cells (microarray)
Microarray Data dataset from our group contained luminal MCF7 cells and 3 basallike/triple negative (MDA-MB-157, MDA-MB-231, Hs578T and BT549) BC cell lines.
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Figure 4.42 RBMS3 is inversely correlated with ESRP1 and ESRP2 expression in
TNBC cells compared to luminal BC cells
Western blot analysis contained 2 luminal cell lines (MCF7 and T47D) and 7 TNBC cell
lines (including inflammatory BC cells SUM149 and 6 BLBC cells MDA-MB-157, MDAMB-231, Hs578T, BT549, SUM159 and SUM1315).
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Figure 4.43 Schematic of the domain organization of ESRP1, ESRP2 and RBMS3
DEDD: DnaQ-like 3’-5’ Exonuclease Domain superfamily; RRM: RNA Recognition
Motif; DUF: Domain of Unknown Function. RBMS3 contains two RRMs that are known
to bind single-stranded RNAs.
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Figure 4.44 Schematic workflow for establishment of RBMS3 overexpression and
ESRP knockout cell lines
All knockout cell lines were established on the Cas9-expressing cells. Each transfected cell
line was either selected by corresponding drug for at least two weeks or cell sorting. All
knockout cells were screened for single clones. A total of 14 cell lines were subjected to
functional assays and RNA-seq.
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Figure 4.45 Establishment of ESRP-KO and RBMS3-OE cell lines
Western blot analysis of RBMS3 overexpression and ESRP knockout cell lines. (Ctrl
denotes control/parental cells; E1KO denotes ESRP1 knockout; E2KO denotes ESRP2
knockout; DKO denotes ESRP1 and 2 double knockout; DKOR3 denotes ESRP 1 and 2
double knockout combined with RBMS3 overexpression)
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Figure 4.46 The effect of TGF- β1 on MCF7-derived or T47D-derived cells
Combination of RBMS3 expression and TGF- β1 treatment (10 ng/mL) does not contribute
to typical mesenchymal appearance in MCF7 or T47D cells with loss of ESRP1 and ESRP2
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Figure 4.47 RBMS3 facilitates Slug-induced EMT
MCF7-derived cell lines stably expressed Slug-mCherry vector were plated for 24 hours
and treated with TGF-β1. Cells were cultured for 9 days and photographs were taken.
Representative images of the cells and fluorescence intensity of mCherry from the same
views are shown. Scale bars, 400 µm. Expression level of Slug was confirmed by Western
blot (data not shown). Red arrows show the area of cells with mesenchymal-like
morphology. The ratio between the longest diameter and the shortest diameter of the cells
was determined. Cells for which the ratio was more than 2.1 was regarded as ‘spindle-like
shaped cells’. Data are shown as mean ± SD from three independent experiments. (*p <
0.05, **p < 0.01, *** < 0.001)
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4.10 RBMS3 and ESRPs play different roles in cell proliferation and migration
To examine the functions of ESRPs in detail and compare with RBMS3, we first
performed cell viability assay. Compared to MCF7-Cas9 control cells, loss of ESRP2
demonstrated significantly elevated cell growth, indicative of potent growth suppressive
role of ESRP2. Unlike ESRP2, loss of ESRP1 had little effect on MCF7 cell viability. Loss
of both ESRPs showed a slight increase of cell growth compared to control, whereas
overexpression of RBMS3 induced a significantly increased cell growth in MCF7-ESRP
DKO cells. RBMS3 induced little/no increase on cell growth compared with MCF7 or
T47D control cells. Loss of ESRP1 caused mild reduction of cell viability compared to
T47D-Cas9 control cells, suggesting that ESRP1 has mild growth-promoting function in
T47D cells. Conversely, loss of ESRP2 resulted in significant increase in T47D cell
viability, confirming the strong growth inhibitory effect of ESRP2 in luminal BC cells.
T47D-ESRP-KO cells showed mild reduction of viability compared to T47D-Cas9 control
cells, and T47D-ESRP DKO-RBMS3 cells showed significantly increased cell growth
compared to T47D-ESRP DKO cells, suggesting that RBMS3 promotes cell growth under
depletion of both ESRPs (Figure 4.48). Based on cell migration assay, ESRP1 significantly
suppressed MCF7 and T47D cell migration. ESRP2, however, appeared to promote MCF7,
but not T47D, cell migration. Loss of both ESRPs significantly promoted T47D, but not
MCF7, cell migration compared to control. As expected, RBMS3 induced migration of
T47D and MCF7 cells with loss of both ESRPs (Figure 4.49). Scratch assay suggested that
cells with RBMS3 or loss of ESRP1 had faster wound closure rate, further confirming the
migration suppressive role of ESRP1 in both cell lines. Loss of ESRP2 led to slower closure
in MCF7, but not in T47D cells, which is consistent with results of migration assay (Figure
4.50). Compared to Cas9 control cells, loss of ESRP1 greatly facilitated colony formation,
whereas loss of ESRP2 inhibited colony formation. Surprisingly, fewer colonies were
formed when both ESRPs are lost, this may be due to the contradictory roles of ESRP1 and
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ESRP2 on colony formation (Figure 4.51). Mammosphere assay showed that cells with
loss of ESRPs, especially ESRP2, formed irregular mammospheres, unlike the rounded
ones formed by control cells. In addition, loss of ESRP1 or ESRP2 affected formation of
large mammospheres, but not small mammospheres (Figure 4.52-53). When grown in 3D
Matrigel, expression of RBMS3 or loss of ESRPs promoted formation of small
mammospheres in T47D cells. Conversely, loss of either ESRP1 or ESRP2 showed little
effect on mammosphere formation compared with control (Figure 4.54). When cells were
cultured in round-bottomed low-attach 96-well plates, we noticed that RBMS3 or loss of
ESRP2 appears to promote cell dispersion (Figure 4.55). Collectively, our results indicate
that ESRP1, ESRP2 and RBMS3 play distinct roles in BC: While ESRP1 primarily inhibits
migration, ESRP2 mainly suppresses proliferation and promotes migration. The opposite
functions of ESRP1 and ESRP2 on cell migration may be explained by the requirement of
mammary branching morphogenesis during development, possibly controlled by the
relative endogenous levels of these two proteins.
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Figure 4.48 ESRP1, ESRP2 and RBMS3 play distinct roles on cell viability
103 cells were seeded in 100 µL medium and cultured for indicated time. 50 µL medium
was removed and 50 µL Cell-Glo Titer 2.0 reagent added to each well before testing. Plates
were shaken 5 minutes and stabilized for another 5 minutes. All values were normalized to
MCF7 or T47D cells. Data are shown as mean ± SD from two independent experiments.
All values are compared to Cas9 control except that RBMS3-OE is compared to wild-type
control. In the MCF7-derived cell lines, p<0.05 (ESRP DKO vs. Control), p<0.01 (ESRP
DKO-RBMS3 vs. Cas9), p<0.001 (ESRP2 vs. Cas9), NS (RBMS3 vs. Control, ESRP1 KO
vs. Cas9). In the T47D-derived cell lines, p<0.05 (ESRP1 KO vs. Cas9, ESRP DKO vs.
Cas9), p<0.001 (ESRP2 vs. Cas9), NS (RBMS3 vs. Control, ESRP DKO vs. Cas9)
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Figure 4.49 ESRP1, ESRP2 and RBMS3 play distinct roles on cell migration
5.0 x104 cells were seeded on top of the Matrigel in the upper Boyden chamber and the
bottom chamber was filled with culture medium containing EGF (10 ng/mL) as the
chemoattractant. After 48 hours, the underside of the Boyden chamber membrane was
fixed, stained and counted. Data are shown as mean ± SD from three independent
experiments. All values are compared to wild-type control. (*p < 0.05, **p < 0.01, *** <
0.001)
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Figure 4.50 ESRP1, ESRP2 and RBMS3 play distinct roles on wound healing
MCF7-derived (A) and T47D-derived (B) cells were grown to around 90% confluency and
serum-starved overnight. A scratch (‘wound’) was inflicted to the cell layer. Wound
closure was photographed at 0 and 24 hour. Cell migration rate was calculated upon the
difference of gap width at 24 hour compared to 0 hour depending on the speed of wound
closure. Data are shown as mean ± SD from two independent experiments. All values are
compared to wild-type control.
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Figure 4.51 ESRP1, ESRP2 and RBMS3 have distinct roles on colony formation
103 cells were seeded in the upper layer of the soft agar plate and grown for two weeks.
Colonies were stained with crystal violet and counted under four random views. Data are
shown as mean ±SD from three independent experiments. (**p < 0.01)
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Figure 4.52 ESRP1, ESRP2 and RBMS3 have distinct effects on mammosphere
formation
Tumorsphere formation was assessed in MCF7 cell with or without loss of ESRPs and in
the presence or absence of RBMS3. 105 cells were seeded in 6-well plate using commercial
mammosphere-forming media and cultured for two weeks. Representative images of seven
MCF7-derived cell lines are shown. Scale bars, 1000 µm.
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Figure 4.53 RBMS3 or loss of ESRPs inhibits mammosphere formation
Graphic representation of tumorsphere counts based on tumorsphere size (30 µm) in
MCF7-derived cell lines from tumorsphere formation assay. Data are shown as mean ±SD
from twenty independent views.
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Figure 4.54 RBMS3, or loss of ESRPs, promotes formation of small tumorsphere
clusters
Representative images of 3D on-top Matrigel culture in MCF7-derived cell lines.1.5x 104
cells were seeded on a layer of Matrigel and 10% Matrigel was covered on top. Cells were
culture and photographed at day 4.
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Figure 4.55 Representative images of adhesion-independent growth of luminal BC
cells with or without ESRPs and/or RBMS3
Adhesion-independent growth of 14 luminal BC-derived clones were examined. Briefly,
0.8x103 cells were seeded in 96-well round bottom ultralow-attachment plates. Cells were
cultured for up to one week and photographs were taken daily. Shown are representative
images of day 1 and day 7. All cells are seeded in triplicates.
4.11 Identification of Alternative Splicing Events Regulated by ESRPs and RBMS3
While much is known about transcriptional regulation of EMT, alternative splicing
of genes and their contributions to the morphological conversion accompanying EMT have
not been comprehensively investigated. Although ESRP1 and ESRP2 have been shown to
inhibit AS events during EMT, it remains unclear whether RBMS3 also alter splicing of
genes and if these three RBPs share common targets that are directly involved in EMT. To
dissect the mechanism by which ESRP1, ESRP2 and RBMS3 regulate EMT, we used the
established cell culture model and RNA-seq analysis to assess changes in transcriptional
programs. Briefly, as mentioned above, we knocked out each or both of the ESRP1 and
ESRP2, or overexpressed RBMS3 in T47D cells. A total of seven clones (T47D, T47DCas9, T47D-RBMS3, T47D-ESRP1 KO, T47D-ESRP2 KO, T47D-ESRP DKO and T47DESRP DKO-RBMS3) were sent for RNA-seq. To deduce regulon of the three RBPs from
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our dataset, we paired matched the expression results of each clone to generate lists of
DEGs (marked as A, B, C, D, E, and F) potentially regulated by the corresponding RBP
(Figure 4.56). By cross-checking each list, information of potential regulon was obtained.
Depletion of ESRPs affected expression of 4705 transcripts, 49.3% of which were
downregulated, whereas overexpression of RBMS3 affected a smaller set of 1307
transcripts, 61% of which were upregulated (Figure 4.57A). Interestingly, by comparing
lists B and C, significantly less transcripts were affected by RBMS3 when ESRPs were
already depleted, revealing similar regulatory functions for these RBPs. Comparison of
lists E and F showed that the number of genes regulated by ESRPs and RBMS3 is more in
‘EMT’ than in ‘MET’ process (Figure 4.57B). Among the 71 and 2096 consistently
regulated transcripts, only 14 were potentially shared by ESRP(s) and RBMS3 (Figure
4.57C). A heatmap of the top 60 DEGs is shown for RBMS3 and ESRP depletion lists
(Figure 4.57D).
We also performed AS analysis in RNA-seq data using R software to individually
quantify and analyze differences in AS events. The number of top AS events were listed
and compared. Among all AS events, 39 events were shared by ESRP1 and ESRP2.
Another 39 events were shared by ESRP1 and RBMS3; and 53 were shared by ESRP2 and
RBMS3. Interestingly, one event was found to be commonly regulated by all three RBPs
(Figure 4.58A). Next, we examined five common types of alternative isoform expression
events, each capable of producing multiple mRNA isoforms from a gene through AS.
These AS events included 3’ alternative splicing (A3SS), 5’ alternative splicing (A5SS),
exon skipping (SE), retained intron (RI) and mutually exclusive exon (MXE). A
comprehensive set of 9808 events of these five types was derived from the analysis in
T47D-RBMS3 versus control cells. 9461 and 9874 events were observed in T47D-ESRP1
KO and T47D-ESRP2 KO versus control cells, respectively. These events were then
ranked to generate top splicing lists based on reads. As observed for transcriptional targets,
the overlap between alternatively spliced exons regulated by these RBPs was moderate. In
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T47D-RBMS3 versus control T47D cells, MXE event occurs most frequently in the top
splicing list. A3SS and A5SS events occur at similar moderate levels, whereas RI event
appears least frequently (Figure 4.58B).

Figure 4.56 Schematic of analytic workflow of RNA-seq dataset
Expression sets of these four cell lines were pair-matched and compared by FC, generating
lists of DEGs marked as group A, B, C, D, E and F. FC greater than 0.5 is considered as
differentially expressed. By cross-checking each list, information on the potential regulon
of each RBP will be inferred.
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Figure 4.57 Expression Regulation by ESRP1, ESRP2 and RBMS3
(A) Number and percentage of transcripts up- or downregulated more than 1.5 fold upon
depletion/overexpression of the indicated RBPs.
(B) Number of DEGs (>1.5 fold) present in each list.
(C) Number DEGs consistently present or consistently regulated in both list B and C, or A
and D. Circles represent the number of DEGs regulated by the indicated RBPs. Overlap
between gene expression changes is shown in blue.
(D) Heatmap for the top 60 DEGs in RNA-seq dataset.
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Figure 4.58 Splicing Regulation by ESRP1, ESRP2 and RBMS3
(A) Overlap between alternative splicing changes observed upon RBP depletion or
overexpression.
(B) Number of splicing changes upon depletion of the RBPs across categories of alternative
splicing events. A3SS = 3’ alternative splice site, A5SS = 5’ alternative splice site, SE =
exon skipping, RI = retained intron, MXE = mutually exclusive exon
4.12 Proposed Model of ESRPs and RBMS3 in BC
Normal mammary cells express potent epithelial regulators, such as ESRPs, to
govern epithelial identity and suppress EMT. In normal ductal cells and luminal BC cells,
TGF-βr signaling remains at minimal/undetected level. Upon stimulation by external TGF112

β, cells respond through an intricate balance of Smad-dependent or independent signaling,
eventually driving the tumor-supressing arm of TGF-βr signaling. During advanced BC
stages, chronic activation of high levels of TGF-βr signaling disables/inactivates the tumorsuppresing arm, which shifts the equilibrium to the tumor-promoting arm and leads to
activation of oncogenes like RBMS3. RBMS3 upregulates Smad proteins and further
enhances TGF-βr signaling, which induces expression of EMT master regulators,
eventually leading to metastatic behaviors of cancer cells, characterized by loss of
epithelial polarity and conversion into an elongated, migratory and invasive phenotype
(Figure 4.59) [55].
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Figure 4.59 Proposed model on RBMS3 and ESRPs
Mammary ductal cells possess intrinsic apical-basal epithelial polarity maintained by
several types of cellular junctions. TGF-β signaling is initiated by ligand-induced
oligomerization of serine/threonine receptor kinases and phosphorylation of the
cytoplasmic molecules Smad2/3, resulting in their interactions with transducer Smad4 and
translocation into the nucleus. Activated Smads regulate diverse biological effects by
partnering with other transcription factors, leading to cell-state specific modulation of
transcription. Specifically, in premalignant cells, cell cycle arrest and apoptosis are two
common pathways that are regulated by TGF-β signaling to suppress tumor formation. On
the contrary, during later stage of tumorigenesis, the tumor suppressing arm of TGF-β is
disabled, shifting to tumor-promoting arm of TGF-β signaling, leading to activation of
oncogenes like RBMS3. RBMS3 upregulates TGF-β-regulated EMT master regulators
(Snail, Slug and Twist, etc) and promote tumor progression by transcriptional control of
EMT genes, eventually resulting in tumor progression. (Orange shape indicates ligand;
Blue and purple hooked shapes indicate serine/threonine receptor kinases; Beige egged
shape with black outline indicates nucleus; Black turning arrow indicate ‘activation of
transcription’; Double wave indicates DNA; Single wave indicates RNA)
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CHAPTER 5. DISCUSSION

For the past decade, increasing attention has been drawn to the posttranscriptional network of EMT, which involves alternative splicing, noncoding RNA
and mRNA stability, etc. RBMS3 is a possible post-transcriptional regulator that popped
out from our microarray dataset. So far the function of RBMS3 in tumorigenesis has
been seemingly controversial. Despite being downregulated in TCGA overall breast
tumor patients compared to normal counterparts, RBMS3 shows increased expression
among invasive BLBC cells. Hence, it may be difficult to interpret the actual function
of RBMS3 solely based on TCGA data due to heterogeneous nature of breast tumors.
Intriguingly, Oncomine dataset also showed that RBMS3 is highly expressed in the
immune cells, which indicated RBMS3 could potentially play a role in the immune
system (data not shown). Another interesting conundrum is that, while the expression of
both ESRPs are low in normal epithelium, they are upregulated in luminal BC cells and
downregulated in invasive fronts.
In an attempt to study RBMS3 and ESRPs in detail, we took the advantage of
several BLBC cell lines and luminal BC cell lines. These two subtypes of BC cells are
commonly used to study the EMT process as they nicely represent the epithelial state
and mesenchymal state, respectively. As luminal BC cells and basal-like BC cells arise
from genetically-different backgrounds, we were not unexpected to see inconsistencies
on the viability assay between MCF7 cell and BT-549 cells. Failure to elicit effect on
proliferation in MCF7 cells does not imply that RBMS3 cannot not involved in cell
proliferation, as its effect could neutralized or mitigated by other potent factors in the
MCF7 cells. Surprisingly, unlike previous studies that revealed largely redundant roles
for ESRP1/2 on cell motility in several cancers [153-155], we observed differential
functions of ESRP1/2 on luminal BC cell migration and proliferation. While ESRP1/2
are essential to suppress EMT, loss of ESRPs is not sufficient to drive mesenchymal

phenotype in luminal BC cells, suggesting that other core molecules may be involved in
the EMT process. Our functional assays revealed that RBMS3 has important roles on
cell migration, invasion and CSC self-renewal. Specifically, CSCs are thought to be
responsible for drug resistance and disease relapse, and the rationale behind
mammosphere assay is that only CSCs are able to form individual mammospheres in the
specialized medium under suspension condition. Compared to the control cells that
formed regular-sized and sphere-shaped mamospheres, RBMS3 overexpression led to
significantly increased numbers of small and irregular-shaped clusters which tend to be
quite loose and unstable, reminiscent of what is observed in the MCF7 cells with
knockdown of E-cadherin. Indeed, formation of small and loose cell cluster appears to
be more favorable for cancer cell dissemination in the circulation as it may increase the
efficiency of spreading and the chances of forming metastasis.
To study whether RBMS3 serves as a central player in the EMT process, we
induced RBMS3 expression in T47D and MCF7 luminal BC cells as well as in those
with loss of both ESRPs. T47D and MCF7 cells are widely studied in breast cancer
mechanisms. While both being estrogen receptor-positive, they have intrinsically
distinct genetic background and molecular profiles as previous studies from 2D gel and
mass spectrometry have revealed that several proteins involved in cell growth
stimulation and anti-apoptotic mechanisms are more strongly expressed in T47D than
MCF7 cells. Additionally, MCF7 cells are reported TP53 wildtype, while T47D cells
are TP53 mutant. These reasons may be at least partially responsible for the
inconsistencies between MCF7- and T47D-derived cell lines observed in our functional
assays. Specifically, since T47D-ESRP DKO and T47D-ESRP DKO-RBMS3 cells grew
in clusters and attached loosely to culture dish, it may be possible that a small portion
of the cells were lost at medium removal step during cell viability assay, affecting the
final measurement and leading to lower values. Unfortunately, we failed to observe
notable morphological or molecular changes to mesenchymal phenotype. However,
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upon overexpression of EMT transcription factor Slug, we observed that T47D-ESRP
DKO-RBMS3 cells transformed into a typical mesenchymal morphology, characterized
by spindle-like shape, at a much faster rate than that of the T47D-ESRP DKO cells,
indicating that T47D-ESRP DKO-RBMS3 cells reside in a place that is closer to the
mesenchymal state than the T47D-ESRP DKO cells. These data also inform us that other
essential factors may also be engaged in the EMT process. To elucidate this, coimmunoprecipitation of RBMS3 followed by liquid chromatography-mass spectrometry
(LC-MS) may be performed to identify potential RBMS3-interacting partners.
Alternatively, we may perform stable isotope labeling by essential nutrients in cell
culture (SILEC) for LC-MS analysis. Furthermore, loss of both ESRPs conquered the
apoptotic effect induced by long term expression of EMT transcription factors,
suggesting that ESRPs may be responsible in regulating apoptotic pathways that are
suppressed in mesenchymal cells.
To date, the mechanistic role of RBMS3 in human development has not been
established. The one and only study for in vivo function of RBMS3 was described in the
zebrafish model, where RBMS3 is transiently expressed in the cytoplasm of migrating
cranial neural crest (CNC) in the pharyngeal arches during cartilage differentiation.
RBMS3 spatiotemporally controls the timing and duration of the TGF-βr signaling
within CNC cells through transcript stability of TGF-βr pathway components, which
influences proliferation and initial differentiation of prechondrogenic CNC. TGF-βr
pathway promotes Sox9-dependent transcriptional activity on the a1 (II) collagen gene
(COL2A1) enhancer to induce chondrogenesis [156]. That being said, a certain threshold
of TGF- βr signaling is likely to be required to drive prechondrogeneic cells down the
cartilage lineage. Once become committed to chondrogenesis, Rbms3 expression is shut
down in these cells [136]. For years TGF-β, a potent pleiotropic cytokine, has been
known as an inducer of cell arrest in benign cells and early-stage tumors, but also a
contributor of breast cancer cellular heterogeneity and metastasis. This mysterious
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phenomenon or conundrum is considered as the ‘TGF-β’ paradox. Unfortunately, due to
the dual nature of TGF-β in BC patients, it is unlikely to be utilized as a tumor marker
to distinguish patients with high risk of metastasis [157]. To date, regulators involved
in TGF-β signaling during tumor progression and the underlying mechanisms still
remain to be clarified. Despite of difficulty, increasing evidence has revealed that the
diversity of TGF-β response is determined by combinatorial usage of core pathway
components [158]. Therefore, unraveling the activities of these central players is crucial
to understand the execution of TGF-β-mediated EMT. It is known that expression of Ecadherin is suppressed by Snail [47], which is shown in this study to be induced by
RBMS3-mediated TGF-β/Smad signaling.
We based our study on the finding in the zebrafish model. In our studies, we
verified the link between TGF-β and RBMS3 in breast cancer cells and provided detailed
mechanisms for RBMS3-mediated activation of TGF-β/Smad signaling. Our findings on
RBMS3 have at least four broader impacts: 1) It furthers our understanding of TGF-β
pathway; 2) It enables the possibility of using RBMS3, instead of TGF-β, as a potential
tumor marker to distinguish patients with higher probability of metastasis; 3) It
facilitates the discovery of other essential mRNA regulators important for EMT; 4)
Understanding the importance of RBMS3 help us to further study the role of RBMS3 in
human development and other biological processes.
In bone-metastatic cancer cells, connective tissue growth factor (CTGF) is highly
expressed and secreted [159]. CTGF is known to be expressed at low levels in luminal
BC cells and found to mediate TGG-β-induced apoptosis in MCF7 cells. Interestingly,
we found significant downregulation of CTGF in luminal BC cells with expression of
RBMS3, suggesting that even though RBMS3 may conquer TGF-β-mediated apoptosis
and cytostasis, its expression alone failed to elicit TGF-β-mediated metastasis in luminal
BC cells. We also noticed that depletion of RBMS3 downregulated Smad2 and Smad3
but not Smad4. This suggest that RBMS3 tightly controls the total pool of Smad2 and
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Smad3 through regulating mRNA stability. The inconsistency between qPCR and Act D
stability assay, reflected by unaffected level of Smad4 mRNA and decreased Smad4
mRNA stability in BT-549 RBMS3-KO compared to control cells, suggest that Smad
may also be regulated through other post-transcriptional or translational mechanisms.
Interesting, when we induce BT549 control and RBMS3-KO cells with TGF-β1, we
observed downregulation of Slug and Twist and upregulation of Snail in BT549 cells
that is absent in the RBMS3-KO cells, suggesting a possible feedback loop for the cells
to maintain the equilibrium of EMT genes.
Using Kaplan-Meier Plotter, we discovered a correlation between RBMS3
expression and prognosis in BC. The prognosis of advance stage BC patients with high
expression RBMS3 was poor compared with those with low expression of RBMS3. Here
we demonstrated that RBMS3 is closely associated with BC malignancy, suggesting
RBMS3 may serve as a novel prognostic marker and therapeutic target for malignant
BC. Beyond our study is whether RBMS3 exert the same tumor-promoting roles in vivo.
As for future directions, in vivo studies should be performed to find out whether RBMS3
is critical for tumorigenicity of TNBC and whether RBMS3 inhibitors may suppress the
tumorigenicity by inhibiting TGF-β pathway.
From our RNA-seq analysis, we discovered several expression events that are
potentially co-regulated by ESRP1, ESRP2 and RBMS3. However, whether these DEGs
are direct targets or consequence of ‘butterfly effect’ is still unknown. Additionally, we
also identified several promising AS events. These targets should be validated in order
to identify critical ones that are indispensable and consistently changed during the EMT
process. The study of these DEGs will greatly enhance our understanding of the post transcriptional network and landscape of EMT and metastasis. Additionally, we
identified one AS event co-regulated by ESRPs and RBMS3. This AS event was
unpublished and leads to the production of two isoforms of the gene product, which is a
membrane protein that has at least 2-3 isoforms. One isoform was reported to be closely
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related to mammary tumors. Therefore, it will be interesting to study whether ESRPs
and RBMS3 truly regulate the splicing of this gene and how this process contributes to
EMT.
The characterization of RBMS3 expression in BC during my dissertation
research, including the phenotypic and mechanistic data, answered several questions
about the tumor promoter role of RBMS3. However these data have also raised several
more important pertinent questions. As for further directions, firstly, it may be necessary
to study the biological function of RBMS3 in greater detail. While RBMS3 has been
shown to reduce cell contact and E-cadherin, it will be interesting to study how RBMS3
regulates polarity. In addition, since RBMS3 belongs to the MSSP family and other
members are found to be involved in gene transcription, cell cycle and apoptosis, we
anticipate that the role of RBMS3 on TGF-β-mediated cytostasis and apoptosis is
mediated through transcriptional regulation of c-myc. Secondly, the study of splicing
mechanisms of ESRPs and RBMS3 will provide detailed information on the posttranscriptional landscape of EMT. Thirdly, according to TCGA data on Oncomine
website, RBMS3 shows a differential expression pattern in immune cells of breast
carcinoma. Fourthly, a published microarray indicated that knockdown of ER induced
expression of RBMS3, suggesting a potential positive correlation on the hormonal
control of RBMS3. Oppositely, we expect that RBMS3 expression will lead to reduction
of ER, leading to the ER-negative phenotype. Fifthly, due to the predominant presence
of RBMS3 in the cytoplasm, it might be involved in other aspects of the RNA
metabolism, such as RNA localization, mRNA decay, translational regulation, etc.
Lastly, the role of RBMS3 in cancer has been controversial. A number of studies have
shown as RBMS3 as a tumor suppressor in pancreatic cancer, epithelial ovarian cancer
and epithelial esophageal carcinoma. However, results from our study have provided
opposite lines of evidence for RBMS3, resulting in the conflict within the field.
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Therefore, it will be necessary to address the in vivo function of RBMS3 in BC by IHC
analysis and mouse studies.
Beyond this study are some bigger questions that are waiting for answers. Firstly,
it is still unclear whether cells at the invasive front are predetermined to serve a leader role
or are simply induced to a leader phenotype due to their close interactions with the
environment. Is RBMS3 expressed only in the leader cells? When do cells begin to express
RBMS3? Is RBMS3 silenced during mesenchymal-epithelial transition (MET) process
after seeding metastasis? How is RBMS3 regulated by the spatiotemporal control of cell
signals? In order to find out the answers, it may be necessary to investigate the microenvironmental context in greater details. Secondly, the on-off switch that drives the
expression of RBMS3, which subsequently triggers TGF-β to work as a tumor promoter
during metastasis, is still unknown. Lastly, the mechanism underlying the transition of
collective movement into widespread dissemination in the metastatic cascade also remains
an open question.
In summary, the study within this dissertation has uncovered a pivotal role of
RBMS3 in maintaining mesenchymal identity and promoting EMT in BC. This study
allows us to explore the potential of using RBMS3 as a classification marker to stratify
high grade tumors with high levels of TGF-β signaling and a diagnostic marker for
developing TNBC treatment strategies. It also provides directions on the identification of
RBMS3-regulated DEGs or splicing patterns that may also serve as diagnostic markers.
These studies will greatly enhance our understanding of the post-transcriptional regulation
of EMT and breast cancer progression.
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Table 5 EMT and apoptosis status in T47D-derived cells with overexpression of
Slug/Snail/Twist or TGF-β treatment (10 ng/mL) at day 9 (post transfection or
treatment).
Cell Lines
Control
RBMS3
ESRP1 KO
ESRP2 KO
ESRP DKO
ESRP DKORBMS3

Slug
Snail
Twist
TGF-β
EMT Apoptosis EMT Apoptosis EMT Apoptosis EMT Apoptosis
+++
+++
+
+++
++

+
+
+
-

++

+
+
+
-

-

+
-

+

+
-

*The number of ‘+’ represents the degree or extent of apoptosis, which is measured by the
number of viable cells. Note that we summarize ‘EMT’ status only based on typical
spindle-like appearance instead of other characteristics or phenotypes.
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APPENDIX
List of Acronyms and Abbreviations
Abbreviation
ANK
ARE
AUF1
BLBC
CCLE
Co-Smad
CSC
CTBP
CTGF
DEG
DMEM
E-cad
ELAV
EMT
ER
ESRP
FACS
FBS
FC
FGFR
GO
HEPES
HER2
HMGA2
hTERT
IHC
JAK
JNK
KC
KEGG
KO
LC-MS
MAPK

Acronym
Ankyrin repeats
AT-rich element
AU-rich element RNA binding protein 1
Basal-like breast cancer
Cancer cell line encyclopedia
Co-regulatory Smad
Cancer stem cell
C-terminal-binding protein
Connective tissue growth factor
Differentially expressed genes
Dulbecco’s Modified Eagle Medium
E-cadherin
Embryonic lethal abnormal vision
Epithelial-Mesenchymal Transition
Estrogen receptor
Epithelial splicing regulatory protein
Fluorescent Activated Cell Sorting
Fetal Bovine Serum
Fold change
Fibroblast growth factor receptor
Gene ontology
Hydroxyethyl piperazineethanesulfonic acid
Human epidermal receptor 2
High mobility group AT-Hook 2
Human telomerase reverse transcriptase
immunohistochemistry
Janus kinase
c-Jun N-terminal kinase
Chemokine ligand 1
Kyoto Encyclopedia of Genes and Genomes
Knockout (of a gene)
liquid chromatography-mass spectrometry
Mitogen-activated protein kinase

MAPKKK
MaSC
MCODE
MET
N/A
NICD
NLS
OE
ORF
PARP
PD-L1
PEST
PKC
PR
qPCR
RAM
RBD
RBMS3
RBP
RBPJ
RRM
SILEC
SMAD

R-Smad
RTK
Ser-Thr
SFRP1
snRNP
TAD
TAK1
TIL
TβR
TGF-β
TNBC
TPM
TRIM
TTP

Mitogen-activated protein kinase kinase kinase
Mammary stem cell
Molecular Complex Detection
Mesenchymal-Epithelial Transition
Not applicable
Notch intracellular fragment
Nuclear localization signal
Overexpression
Open reading frame
poly(ADP-ribose) polymerase
Programmed death ligand 1
Proline (P), glutamic acid (E), serine (S) and threonine (T)
Protein kinase C
Progesterone receptor
Quantitative Real-time Polymerase Chain Reaction
RBPJ-κ association module
RNA binding domain
RNA binding motif single-stranded protein 3
RNA binding protein
Recombination Signal Binding Protein For Immunoglobulin
Kappa J Region
RNA recognition motif
Stable Isotope Labeling by Essential nutrients in Cell culture
Homologies to the Caenorhabditis elegans SMA (‘small’
worm phenotype) and Drosophila MAD (‘Mother Against
Decapentaplegic’) family of genes
Regulatory Smad
Receptor tyrosine kinase
Serine and threonine
Secreted frizzled related protein 1
Small nuclear ribonucleoprotein
Transcriptional activation domain
Transforming growth factor β-activated kinase 1
Tumor-infiltrating lymphocytes
TGF-β receptor
Transforming growth factor beta
Triple-negative breast cancer
Transcript per million
Tripartite motif containing
Tristetraprolin
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VEGF
UTR
ZEB1

Vascular endothelial growth factor
Untranslated region
Zinc finger E-box binding homeobox 1

125

BIBLIOGRAPHY

1.

Gjorevski, N. and C.M. Nelson, Integrated morphodynamic signalling of the

2.

mammary gland. Nat Rev Mol Cell Biol, 2011. 12(9): p. 581-93.
Chatterjee, S.J. and L. McCaffrey, Emerging role of cell polarity proteins in breast

3.

cancer progression and metastasis. Breast Cancer (Dove Med Press), 2014. 6: p.
15-27.
Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2018. CA Cancer J Clin,

4.

2018. 68(1): p. 7-30.
Guise, T.A., Breast cancer bone metastases: it's all about the neighborhood. Cell,

5.

2013. 154(5): p. 957-959.
Minn, A.J., et al., Genes that mediate breast cancer metastasis to lung. Nature,

6.

2005. 436(7050): p. 518-24.
DeSantis, C.E., et al., Breast cancer statistics, 2017, racial disparity in mortality

7.

by state. CA Cancer J Clin, 2017. 67(6): p. 439-448.
Sun, Y.S., et al., Risk Factors and Preventions of Breast Cancer. Int J Biol Sci,

8.

2017. 13(11): p. 1387-1397.
DeSantis, C., et al., Breast cancer statistics, 2013. CA Cancer J Clin, 2014. 64(1):
p. 52-62.

9.

Shi, J., et al., Disrupting the interaction of BRD4 with diacetylated Twist suppresses

10.

tumorigenesis in basal-like breast cancer. Cancer Cell, 2014. 25(2): p. 210-25.
Gao, J.J. and S.M. Swain, Luminal A Breast Cancer and Molecular Assays: A

11.

Review. Oncologist, 2018. 23(5): p. 556-565.
Rakha, E.A. and A.R. Green, Molecular classification of breast cancer: what the

12.

pathologist needs to know. Pathology, 2017. 49(2): p. 111-119.
Shi, J., J. Cao, and B.P. Zhou, Twist-BRD4 complex: potential drug target for

13.

basal-like breast cancer. Curr Pharm Des, 2015. 21(10): p. 1256-61.
Jamdade, V.S., et al., Therapeutic targets of triple-negative breast cancer: a review.

14.

15.

Br J Pharmacol, 2015. 172(17): p. 4228-37.
Leidy, J., A. Khan, and D. Kandil, Basal-like breast cancer: update on
clinicopathologic, immunohistochemical, and molecular features. Arch Pathol Lab
Med, 2014. 138(1): p. 37-43.
Toft, D.J. and V.L. Cryns, Minireview: Basal-like breast cancer: from molecular
profiles to targeted therapies. Mol Endocrinol, 2011. 25(2): p. 199-211.

16.

17.

18.

Tassone, P., et al., BRCA1 expression modulates chemosensitivity of BRCA1defective HCC1937 human breast cancer cells. Br J Cancer, 2003. 88(8): p. 128591.
Botti, G., et al., Programmed Death Ligand 1 (PD-L1) Tumor Expression Is
Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast
Cancer Patients. Int J Mol Sci, 2017. 18(2).
Marra, A., G. Viale, and G. Curigliano, Recent advances in triple negative breast

19.

cancer: the immunotherapy era. BMC Med, 2019. 17(1): p. 90.
Zhou, Y., E.B. Rucker, 3rd, and B.P. Zhou, Autophagy regulation in the
development and treatment of breast cancer. Acta Biochim Biophys Sin (Shanghai),

20.

2016. 48(1): p. 60-74.
Luzzi, K.J., et al., Multistep nature of metastatic inefficiency: dormancy of solitary
cells after successful extravasation and limited survival of early micrometastases.

21.

Am J Pathol, 1998. 153(3): p. 865-73.
Kimbung, S., N. Loman, and I. Hedenfalk, Clinical and molecular complexity of

22.

breast cancer metastases. Semin Cancer Biol, 2015. 35: p. 85-95.
Wan, L., K. Pantel, and Y. Kang, Tumor metastasis: moving new biological insights

23.

into the clinic. Nat Med, 2013. 19(11): p. 1450-64.
Xu, J., S. Lamouille, and R. Derynck, TGF-beta-induced epithelial to mesenchymal

24.

transition. Cell Res, 2009. 19(2): p. 156-72.
Wang, Y. and B.P. Zhou, Epithelial-mesenchymal transition in breast cancer

25.

progression and metastasis. Chin J Cancer, 2011. 30(9): p. 603-11.
Lindsey, S. and S.A. Langhans, Crosstalk of Oncogenic Signaling Pathways during

26.

Epithelial-Mesenchymal Transition. Front Oncol, 2014. 4: p. 358.
Polyak, K. and R.A. Weinberg, Transitions between epithelial and mesenchymal

27.

states: acquisition of malignant and stem cell traits. Nat Rev Cancer, 2009. 9(4): p.
265-73.
Nassar, D. and C. Blanpain, Cancer Stem Cells: Basic Concepts and Therapeutic

28.

Implications. Annu Rev Pathol, 2016. 11: p. 47-76.
Soon, P.S., et al., Breast cancer-associated fibroblasts induce epithelial-to-

29.

mesenchymal transition in breast cancer cells. Endocr Relat Cancer, 2013. 20(1):
p. 1-12.
Dongre, A. and R.A. Weinberg, New insights into the mechanisms of epithelialmesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol, 2019.
20(2): p. 69-84.

127

30.

Kalluri, R. and R.A. Weinberg, The basics of epithelial-mesenchymal transition. J

31.

Clin Invest, 2009. 119(6): p. 1420-8.
Lintz, M., A. Munoz, and C.A. Reinhart-King, The Mechanics of Single Cell and

32.

Collective Migration of Tumor Cells. J Biomech Eng, 2017. 139(2).
Friedl, P., Prespecification and plasticity: shifting mechanisms of cell migration.

33.

Curr Opin Cell Biol, 2004. 16(1): p. 14-23.
Hecht, I., et al., Tumor invasion optimization by mesenchymal-amoeboid

34.

heterogeneity. Sci Rep, 2015. 5: p. 10622.
Wolf, K., et al., Physical limits of cell migration: control by ECM space and
nuclear deformation and tuning by proteolysis and traction force. J Cell Biol, 2013.

35.

201(7): p. 1069-84.
Mak, M., et al., Single-Cell Migration in Complex Microenvironments: Mechanics

36.

and Signaling Dynamics. J Biomech Eng, 2016. 138(2): p. 021004.
Aiello, N.M., et al., EMT Subtype Influences Epithelial Plasticity and Mode of Cell

37.
38.

Migration. Dev Cell, 2018. 45(6): p. 681-695 e4.
Nieto, M.A., et al., Emt: 2016. Cell, 2016. 166(1): p. 21-45.
Giampieri, S., et al., Localized and reversible TGFbeta signalling switches breast

39.

cancer cells from cohesive to single cell motility. Nat Cell Biol, 2009. 11(11): p.
1287-96.
Aceto, N., et al., Circulating tumor cell clusters are oligoclonal precursors of

40.

breast cancer metastasis. Cell, 2014. 158(5): p. 1110-1122.
Cheung, K.J. and A.J. Ewald, A collective route to metastasis: Seeding by tumor

41.

cell clusters. Science, 2016. 352(6282): p. 167-9.
Maddipati, R. and B.Z. Stanger, Pancreatic Cancer Metastases Harbor Evidence

42.

of Polyclonality. Cancer Discov, 2015. 5(10): p. 1086-97.
Reichert, M., et al., Regulation of Epithelial Plasticity Determines Metastatic

43.

Organotropism in Pancreatic Cancer. Dev Cell, 2018. 45(6): p. 696-711 e8.
Scheel, C., et al., Paracrine and autocrine signals induce and maintain

44.

mesenchymal and stem cell states in the breast. Cell, 2011. 145(6): p. 926-40.
Su, J., et al., MicroRNA-200a suppresses the Wnt/beta-catenin signaling pathway

45.

by interacting with beta-catenin. Int J Oncol, 2012. 40(4): p. 1162-70.
Chaffer, C.L., et al., EMT, cell plasticity and metastasis. Cancer Metastasis Rev,

46.

2016. 35(4): p. 645-654.
Nagathihalli, N.S. and N.B. Merchant, Src-mediated regulation of E-cadherin and
EMT in pancreatic cancer. Front Biosci (Landmark Ed), 2012. 17: p. 2059-69.

128

47.

Batlle, E., et al., The transcription factor snail is a repressor of E-cadherin gene

48.

expression in epithelial tumour cells. Nat Cell Biol, 2000. 2(2): p. 84-9.
Lamouille, S., J. Xu, and R. Derynck, Molecular mechanisms of epithelial-

49.

mesenchymal transition. Nat Rev Mol Cell Biol, 2014. 15(3): p. 178-96.
Barrallo-Gimeno, A. and M.A. Nieto, The Snail genes as inducers of cell movement
and survival: implications in development and cancer. Development, 2005.

50.

132(14): p. 3151-61.
Yang, J., et al., Twist, a master regulator of morphogenesis, plays an essential role

51.

in tumor metastasis. Cell, 2004. 117(7): p. 927-39.
Aparicio, L.A., et al., Posttranscriptional regulation by RNA-binding proteins

52.

during epithelial-to-mesenchymal transition. Cell Mol Life Sci, 2013. 70(23): p.
4463-77.
de Moor, C.H., H. Meijer, and S. Lissenden, Mechanisms of translational control

53.

by the 3' UTR in development and differentiation. Semin Cell Dev Biol, 2005. 16(1):
p. 49-58.
Sutherland, J.M., et al., RNA binding proteins in spermatogenesis: an in depth focus

54.
55.

on the Musashi family. Asian J Androl, 2015. 17(4): p. 529-36.
Massague, J., TGFbeta in Cancer. Cell, 2008. 134(2): p. 215-30.
Imamura, T., A. Hikita, and Y. Inoue, The roles of TGF-beta signaling in

56.

carcinogenesis and breast cancer metastasis. Breast Cancer, 2012. 19(2): p. 11824.
Principe, D.R., et al., TGF-beta: duality of function between tumor prevention and

57.

carcinogenesis. J Natl Cancer Inst, 2014. 106(2): p. djt369.
He, W., et al., Hematopoiesis controlled by distinct TIF1gamma and Smad4

58.

branches of the TGFbeta pathway. Cell, 2006. 125(5): p. 929-41.
Zhang, L., et al., RNF12 controls embryonic stem cell fate and morphogenesis in

59.

zebrafish embryos by targeting Smad7 for degradation. Mol Cell, 2012. 46(5): p.
650-61.
Koinuma, D., et al., Arkadia amplifies TGF-beta superfamily signalling through

60.

degradation of Smad7. EMBO J, 2003. 22(24): p. 6458-70.
Derynck, R. and Y.E. Zhang, Smad-dependent and Smad-independent pathways in

61.

TGF-beta family signalling. Nature, 2003. 425(6958): p. 577-84.
Zhang, Y.E., Non-Smad Signaling Pathways of the TGF-beta Family. Cold Spring
Harb Perspect Biol, 2017. 9(2).

129

62.

Yi, J.Y., I. Shin, and C.L. Arteaga, Type I transforming growth factor beta receptor

63.

binds to and activates phosphatidylinositol 3-kinase. J Biol Chem, 2005. 280(11):
p. 10870-6.
Sorrentino, A., et al., The type I TGF-beta receptor engages TRAF6 to activate

64.

65.

TAK1 in a receptor kinase-independent manner. Nat Cell Biol, 2008. 10(10): p.
1199-207.
Bhowmick, N.A., et al., Transforming growth factor-beta1 mediates epithelial to
mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol
Cell, 2001. 12(1): p. 27-36.
Edlund, S., et al., Transforming growth factor-beta-induced mobilization of actin
cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell,

66.

2002. 13(3): p. 902-14.
Xie, F., et al., TGF-beta signaling in cancer metastasis. Acta Biochim Biophys Sin

67.

(Shanghai), 2018. 50(1): p. 121-132.
Gordon, K.J. and G.C. Blobe, Role of transforming growth factor-beta superfamily

68.

signaling pathways in human disease. Biochim Biophys Acta, 2008. 1782(4): p.
197-228.
Derynck, R. and R.J. Akhurst, Differentiation plasticity regulated by TGF-beta

69.

family proteins in development and disease. Nat Cell Biol, 2007. 9(9): p. 1000-4.
Wahl, S.M., J. Wen, and N. Moutsopoulos, TGF-beta: a mobile purveyor of

70.

immune privilege. Immunol Rev, 2006. 213: p. 213-27.
Horbelt, D., A. Denkis, and P. Knaus, A portrait of Transforming Growth Factor
beta superfamily signalling: Background matters. Int J Biochem Cell Biol, 2012.

71.

44(3): p. 469-74.
Wang, Y. and B.P. Zhou, Epithelial-mesenchymal Transition---A Hallmark of

72.

Breast Cancer Metastasis. Cancer Hallm, 2013. 1(1): p. 38-49.
Klaus, A. and W. Birchmeier, Wnt signalling and its impact on development and

73.

cancer. Nat Rev Cancer, 2008. 8(5): p. 387-98.
Clevers, H., Wnt/beta-catenin signaling in development and disease. Cell, 2006.

74.

127(3): p. 469-80.
Gauger, K.J., et al., SFRP1 reduction results in an increased sensitivity to TGF-

75.

beta signaling. BMC Cancer, 2011. 11: p. 59.
Tang, Y., et al., Smad7 stabilizes beta-catenin binding to E-cadherin complex and

76.

promotes cell-cell adhesion. J Biol Chem, 2008. 283(35): p. 23956-63.
Hoover, L.L. and S.W. Kubalak, Holding their own: the noncanonical roles of
Smad proteins. Sci Signal, 2008. 1(46): p. pe48.
130

77.

Dissanayake, S.K., et al., The Wnt5A/protein kinase C pathway mediates motility
in melanoma cells via the inhibition of metastasis suppressors and initiation of an

79.

epithelial to mesenchymal transition. J Biol Chem, 2007. 282(23): p. 17259-71.
Kopan, R., Notch: a membrane-bound transcription factor. J Cell Sci, 2002. 115(Pt
6): p. 1095-7.
Mollen, E.W.J., et al., Moving Breast Cancer Therapy up a Notch. Front Oncol,

80.

2018. 8: p. 518.
Kopan, R. and M.X. Ilagan, The canonical Notch signaling pathway: unfolding the

81.

activation mechanism. Cell, 2009. 137(2): p. 216-33.
Wang, K., et al., PEST domain mutations in Notch receptors comprise an oncogenic

78.

driver segment in triple-negative breast cancer sensitive to a gamma-secretase
82.

inhibitor. Clin Cancer Res, 2015. 21(6): p. 1487-96.
Dontu, G., et al., Role of Notch signaling in cell-fate determination of human

83.

mammary stem/progenitor cells. Breast Cancer Res, 2004. 6(6): p. R605-15.
Bouras, T., et al., Notch signaling regulates mammary stem cell function and

84.

luminal cell-fate commitment. Cell Stem Cell, 2008. 3(4): p. 429-41.
Xie, M., et al., Activation of Notch-1 enhances epithelial-mesenchymal transition

85.

in gefitinib-acquired resistant lung cancer cells. J Cell Biochem, 2012. 113(5): p.
1501-13.
Zhang, L., et al., Activation of Notch pathway is linked with epithelial-mesenchymal

86.

transition in prostate cancer cells. Cell Cycle, 2017. 16(10): p. 999-1007.
Gao, X.J., et al., Nobiletin inhibited hypoxia-induced epithelial-mesenchymal
transition of lung cancer cells by inactivating of Notch-1 signaling and switching

87.

on miR-200b. Pharmazie, 2015. 70(4): p. 256-62.
Bao, B., et al., Notch-1 induces epithelial-mesenchymal transition consistent with

88.

cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett, 2011. 307(1):
p. 26-36.
Timmerman, L.A., et al., Notch promotes epithelial-mesenchymal transition during

89.

90.

cardiac development and oncogenic transformation. Genes Dev, 2004. 18(1): p.
99-115.
Zhao, Z.L., et al., Notch signaling induces epithelial-mesenchymal transition to
promote invasion and metastasis in adenoid cystic carcinoma. Am J Transl Res,
2015. 7(1): p. 162-74.
Kim, R.K., et al., Radiation driven epithelial-mesenchymal transition is mediated
by Notch signaling in breast cancer. Oncotarget, 2016. 7(33): p. 53430-53442.

131

91.

Ito, T., et al., Small cell lung cancer, an epithelial to mesenchymal transition
(EMT)-like cancer: significance of inactive Notch signaling and expression of

92.

achaete-scute complex homologue 1. Hum Cell, 2017. 30(1): p. 1-10.
Saad, S., et al., Notch mediated epithelial to mesenchymal transformation is
associated with increased expression of the Snail transcription factor. Int J

93.

Biochem Cell Biol, 2010. 42(7): p. 1115-22.
Zhang, J., et al., NUMB negatively regulates the epithelial-mesenchymal transition
of triple-negative breast cancer by antagonizing Notch signaling. Oncotarget, 2016.

94.

7(38): p. 61036-61053.
Sczaniecka, M., et al., MDM2 protein-mediated ubiquitination of numb protein:
identification of a second physiological substrate of MDM2 that employs a dual-

95.

site docking mechanism. J Biol Chem, 2012. 287(17): p. 14052-68.
Di Domenico, M. and A. Giordano, Signal transduction growth factors: the
effective governance of transcription and cellular adhesion in cancer invasion.

96.

Oncotarget, 2017. 8(22): p. 36869-36884.
Colomiere, M., et al., Cross talk of signals between EGFR and IL-6R through
JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br

97.

J Cancer, 2009. 100(1): p. 134-44.
Kim, J., et al., EGF induces epithelial-mesenchymal transition through phospho-

98.

Smad2/3-Snail signaling pathway in breast cancer cells. Oncotarget, 2016. 7(51):
p. 85021-85032.
Shirakihara, T., et al., TGF-beta regulates isoform switching of FGF receptors and

99.

epithelial-mesenchymal transition. EMBO J, 2011. 30(4): p. 783-95.
Lei, H. and C.X. Deng, Fibroblast Growth Factor Receptor 2 Signaling in Breast

100.

Cancer. Int J Biol Sci, 2017. 13(9): p. 1163-1171.
Ogunwobi, O.O., et al., Epigenetic upregulation of HGF and c-Met drives

101.

metastasis in hepatocellular carcinoma. PLoS One, 2013. 8(5): p. e63765.
Tam, W.L., et al., Protein kinase C alpha is a central signaling node and

102.

therapeutic target for breast cancer stem cells. Cancer Cell, 2013. 24(3): p. 34764.
Audic, Y. and R.S. Hartley, Post-transcriptional regulation in cancer. Biol Cell,

103.

2004. 96(7): p. 479-98.
Kondo, Y., et al., Crystal structure of human U1 snRNP, a small nuclear
ribonucleoprotein particle, reveals the mechanism of 5' splice site recognition.
Elife, 2015. 4.

132

104.

Lorkovic, Z.J., et al., Evolutionary conservation of minor U12-type spliceosome

105.

between plants and humans. RNA, 2005. 11(7): p. 1095-107.
Wang, Y., et al., Mechanism of alternative splicing and its regulation. Biomed Rep,

106.

2015. 3(2): p. 152-158.
Busch, A. and K.J. Hertel, Evolution of SR protein and hnRNP splicing regulatory

107.

factors. Wiley Interdiscip Rev RNA, 2012. 3(1): p. 1-12.
Pagliarini, V., C. Naro, and C. Sette, Splicing Regulation: A Molecular Device to

108.

Enhance Cancer Cell Adaptation. Biomed Res Int, 2015. 2015: p. 543067.
Liu, Y., et al., Impact of Alternative Splicing on the Human Proteome. Cell Rep,

109.

2017. 20(5): p. 1229-1241.
Lopez de Silanes, I., M.P. Quesada, and M. Esteller, Aberrant regulation of

110.

messenger RNA 3'-untranslated region in human cancer. Cell Oncol, 2007. 29(1):
p. 1-17.
Biamonti, G., et al., Making alternative splicing decisions during epithelial-to-

111.

mesenchymal transition (EMT). Cell Mol Life Sci, 2012. 69(15): p. 2515-26.
Semmler, L., C. Reiter-Brennan, and A. Klein, BRCA1 and Breast Cancer: a
Review of the Underlying Mechanisms Resulting in the Tissue-Specific

112.

Tumorigenesis in Mutation Carriers. J Breast Cancer, 2019. 22(1): p. 1-14.
Silipo, M., H. Gautrey, and A. Tyson-Capper, Deregulation of splicing factors and

113.

breast cancer development. J Mol Cell Biol, 2015. 7(5): p. 388-401.
Orban, T.I. and E. Olah, Emerging roles of BRCA1 alternative splicing. Mol Pathol,

114.

2003. 56(4): p. 191-7.
Cartegni, L., S.L. Chew, and A.R. Krainer, Listening to silence and understanding

115.

nonsense: exonic mutations that affect splicing. Nat Rev Genet, 2002. 3(4): p. 28598.
Moore, M.J., From birth to death: the complex lives of eukaryotic mRNAs. Science,

116.

2005. 309(5740): p. 1514-8.
Griseri, P. and G. Pages, Regulation of the mRNA half-life in breast cancer. World

117.

J Clin Oncol, 2014. 5(3): p. 323-34.
Andreassi, C. and A. Riccio, To localize or not to localize: mRNA fate is in 3'UTR

118.

ends. Trends Cell Biol, 2009. 19(9): p. 465-74.
Mayr, C. and D.P. Bartel, Widespread shortening of 3'UTRs by alternative cleavage

119.

and polyadenylation activates oncogenes in cancer cells. Cell, 2009. 138(4): p.
673-84.
Di Giammartino, D.C., K. Nishida, and J.L. Manley, Mechanisms and
consequences of alternative polyadenylation. Mol Cell, 2011. 43(6): p. 853-66.
133

120.

Ghigna, C., et al., Posttranscriptional Regulation and RNA Binding Proteins in

121.

Cancer Biology. Biomed Res Int, 2015. 2015: p. 897821.
Anantharaman, V., E.V. Koonin, and L. Aravind, Comparative genomics and

122.

evolution of proteins involved in RNA metabolism. Nucleic Acids Res, 2002. 30(7):
p. 1427-64.
Wang, W., et al., HuR regulates cyclin A and cyclin B1 mRNA stability during cell

123.

proliferation. EMBO J, 2000. 19(10): p. 2340-50.
Dong, R., et al., Stabilization of Snail by HuR in the process of hydrogen peroxide

124.

induced cell migration. Biochem Biophys Res Commun, 2007. 356(1): p. 318-21.
Maltzman, W. and L. Czyzyk, UV irradiation stimulates levels of p53 cellular

125.

tumor antigen in nontransformed mouse cells. Mol Cell Biol, 1984. 4(9): p. 168994.
Gratacos, F.M. and G. Brewer, The role of AUF1 in regulated mRNA decay. Wiley

126.

Interdiscip Rev RNA, 2010. 1(3): p. 457-73.
Ciais, D., N. Cherradi, and J.J. Feige, Multiple functions of tristetraprolin/TIS11
RNA-binding proteins in the regulation of mRNA biogenesis and degradation. Cell

127.

Mol Life Sci, 2013. 70(12): p. 2031-44.
Meisner, N.C., et al., mRNA openers and closers: modulating AU-rich elementcontrolled mRNA stability by a molecular switch in mRNA secondary structure.

128.

Chembiochem, 2004. 5(10): p. 1432-47.
Chou, C.F., et al., Tethering KSRP, a decay-promoting AU-rich element-binding

129.

protein, to mRNAs elicits mRNA decay. Mol Cell Biol, 2006. 26(10): p. 3695-706.
Penkov, D., et al., Cloning of a human gene closely related to the genes coding for

130.

the c-myc single-strand binding proteins. Gene, 2000. 243(1-2): p. 27-36.
Wu, Y., et al., Down regulation of RNA binding motif, single-stranded interacting
protein 3, along with up regulation of nuclear HIF1A correlates with poor

131.

prognosis in patients with gastric cancer. Oncotarget, 2017. 8(1): p. 1262-1277.
Chen, J., et al., RBMS3 at 3p24 inhibits nasopharyngeal carcinoma development
via inhibiting cell proliferation, angiogenesis, and inducing apoptosis. PLoS One,

132.

133.

2012. 7(9): p. e44636.
Zhang, T., et al., Low expression of RBMS3 and SFRP1 are associated with poor
prognosis in patients with gastric cancer. Am J Cancer Res, 2016. 6(11): p. 26792689.
Fritz, D. and B. Stefanovic, RNA-binding protein RBMS3 is expressed in activated
hepatic stellate cells and liver fibrosis and increases expression of transcription
factor Prx1. J Mol Biol, 2007. 371(3): p. 585-95.
134

134.

135.

136.

Wu, G., et al., Loss of RBMS3 Confers Platinum-resistance in Epithelial Ovarian
Cancer via Activation of miR-126-5p/beta-catenin/CBP signaling. Clin Cancer Res,
2018.
Lu, C.K., et al., Rbms3, an RNA-binding protein, mediates the expression of Ptf1a
by binding to its 3'UTR during mouse pancreas development. DNA Cell Biol, 2012.
31(7): p. 1245-51.
Jayasena, C.S. and M.E. Bronner, Rbms3 functions in craniofacial development by
posttranscriptionally modulating TGF-beta signaling. J Cell Biol, 2012. 199(3): p.
453-66.

137.
138.

Song, J., EMT or apoptosis: a decision for TGF-beta. Cell Res, 2007. 17(4): p. 28990.
Grimshaw, M.J., et al., Mammosphere culture of metastatic breast cancer cells

139.

enriches for tumorigenic breast cancer cells. Breast Cancer Res, 2008. 10(3): p.
R52.
Wang, J., et al., TSPAN31 is a critical regulator on transduction of survival and

140.

apoptotic signals in hepatocellular carcinoma cells. FEBS Lett, 2017. 591(18): p.
2905-2918.
Dong, C., et al., Loss of FBP1 by Snail-mediated repression provides metabolic

141.

advantages in basal-like breast cancer. Cancer Cell, 2013. 23(3): p. 316-31.
Hong, Y., et al., PPARgamma mediates the effects of WIN55,212-2, an synthetic
cannabinoid, on the proliferation and apoptosis of the BEL-7402 hepatocarcinoma

142.

cells. Mol Biol Rep, 2013. 40(11): p. 6287-93.
Ashburner, M., et al., Gene ontology: tool for the unification of biology. The Gene

143.

Ontology Consortium. Nat Genet, 2000. 25(1): p. 25-9.
The Gene Ontology, C., The Gene Ontology Resource: 20 years and still GOing

144.

strong. Nucleic Acids Res, 2019. 47(D1): p. D330-D338.
Zhou, Y., et al., Metascape provides a biologist-oriented resource for the analysis

145.

of systems-level datasets. Nat Commun, 2019. 10(1): p. 1523.
Gyorffy, B., et al., An online survival analysis tool to rapidly assess the effect of
22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

146.

Breast Cancer Res Treat, 2010. 123(3): p. 725-31.
Mani, S.A., et al., The epithelial-mesenchymal transition generates cells with

147.

properties of stem cells. Cell, 2008. 133(4): p. 704-15.
Singh, A. and J. Settleman, EMT, cancer stem cells and drug resistance: an
emerging axis of evil in the war on cancer. Oncogene, 2010. 29(34): p. 4741-51.

135

148.

Morel, A.P., et al., Generation of breast cancer stem cells through epithelial-

149.

mesenchymal transition. PLoS One, 2008. 3(8): p. e2888.
Chang, J.C., Cancer stem cells: Role in tumor growth, recurrence, metastasis, and

151.

treatment resistance. Medicine (Baltimore), 2016. 95(1 Suppl 1): p. S20-5.
Massague, J., A very private TGF-beta receptor embrace. Mol Cell, 2008. 29(2): p.
149-50.
Tang, X., et al., SIRT7 antagonizes TGF-beta signaling and inhibits breast cancer

152.

metastasis. Nat Commun, 2017. 8(1): p. 318.
Bebee, T.W., et al., The splicing regulators Esrp1 and Esrp2 direct an epithelial

153.

splicing program essential for mammalian development. Elife, 2015. 4.
Ishii, H., et al., Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2)

154.

suppress cancer cell motility via different mechanisms. J Biol Chem, 2014. 289(40):
p. 27386-99.
Warzecha, C.C., et al., ESRP1 and ESRP2 are epithelial cell-type-specific

150.

155.

regulators of FGFR2 splicing. Mol Cell, 2009. 33(5): p. 591-601.
Warzecha, C.C., et al., The epithelial splicing factors ESRP1 and ESRP2 positively
and negatively regulate diverse types of alternative splicing events. RNA Biol,

156.

2009. 6(5): p. 546-62.
Furumatsu, T., et al., Smad3 induces chondrogenesis through the activation of

157.

SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem, 2005. 280(9): p.
8343-50.
Chiechi, A., et al., Role of TGF-beta in breast cancer bone metastases. Adv Biosci

158.

Biotechnol, 2013. 4(10C): p. 15-30.
Ikushima, H. and K. Miyazono, TGFbeta signalling: a complex web in cancer

159.

progression. Nat Rev Cancer, 2010. 10(6): p. 415-24.
Kim, B., et al., A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer cells
Promotes Tumor Progression in Bone. J Bone Miner Res, 2019.

136

VITA

Education
2015-Present Ph.D. in Molecular and Cellular Biochemistry, University of Kentucky
2012–2014

M.S. in Molecular, Cellular and Developmental Biology, University of
Kentucky

2008-2012

B.S. in Biotechnology, South Medical University, China

Professional Experience
2012-2014

Teaching Assistant in Intro to Microbiology, Principles of Genetics and
Principles of Biology II, University of Kentucky

Academic Award
2019

Selected as the Representative for the University of Kentucky to Apply for
the National Cancer Institute-Predoctoral to Postdoctoral Transition
Fellowship (F99/K00)

2015-Present Graduate Assistantship, University of Kentucky
2012-2014

Teaching Assistantship, University of Kentucky

2011

South Medical University Undergraduate Scholarship Award

2011

First Place in Comprehensive Quality Assessment, School of
Biotechnology, South Medical University, China

2008-2009
2008

Merit Student, South Medical University, China
Top Ten Excellent Female Student Award, South Medical University, China

137

Publication
Zhou YT, Rucker E, Zhou BP. Autophagy regulation in the development and treatment of
breast cancer. Acta Biochim Biophys Sin(Shanghai), 2016 Jan 48(1):60-74
Hong YH, Zhou YT, et al. PPARγ mediates WIN55,212-2 induced apoptosis of BEL-7402
hepatocarcinoma cells. Molecular Biology Report, 2013.
Liu YJ, Li H, Zhou YT, et al. Procaryotic Expression and Multi-Clonal Preparation of
PfRPA2. Journal of Tropical Medicine, 2012.12(6)
Xiao SH, Zhou YT, et al. Effect of Activation of Cannabinoid Receptor by THC on
Proliferation and Apoptosis of Hepatoma Bel-7402 Cells. Lishizhen Medicine and Materia
Medica Research, 2012. 23(5)
Zhu XQ, Hu JX, Zhou YT, et al. Effect of the cannabinoid receptor activation by THC on
proliferation and apoptosis of cancer A549 cells. Acta Med Univ Sci Technol Huazhong,
2011;40(5):354-358
Wang Y, Zhou YT, et al. The effect of the activation of cannabinoid receptor WIN-55 2122 on the proliferation and apoptosis of hepatoma HepG2 cells. Chinese J of Cell and
Molecular Immunol, 2010;26(4): 344-348
Zhu XQ, Zhou YT, et al. The effect of the activation of cannabinoid receptor THC on the
proliferation and apoptosis of hepatoma HepG2 cells. Acta Med Univ Sci Technol
Huazhong, 2010;39(3): 376-380

Oral Presentation
2018

“RBMS3 Promotes Basal-like Breast Cancer by Regulating TGF-β Signaling”
Data Club Presentation
Department of Molecular and Cellular Biochemistry, University of Kentucky

2018

“The Role of RNA Binding Protein RBMS3 in Basal-like Breast Cancer”
138

Departmental Seminar Presentation
Department of Molecular and Cellular Biochemistry, University of Kentucky

2017

“The Role of Glucocorticoid Receptor-Mediated Hippo Signaling in Breast
Cancer Cell Stemness and Chemoresistance”
Departmental Seminar Presentation
Department of Molecular and Cellular Biochemistry, University of Kentucky

2016

“Impaired SIRT1 Activity and Huntington’s Disease”
Departmental Seminar Presentation
Department of Molecular and Cellular Biochemistry, University of Kentucky

2015

“lncRNA BCAR4 and Breast Cancer Metastasis”
Departmental Seminar Presentation
Department of Molecular and Cellular Biochemistry, University of Kentucky

2013

“PPARγ Mediates WIN55,212-2, a Synthetic Cannabinoid, on the Proliferation
and Apoptosis of Liver Cancer Cells”
The Sixth Annual World Cancer Congress, Xi’An, Shanxi, China

139

